Porous carbon particles for treating biofilm-mediated diseases and antibiotic resistance

Porous carbon particles with controlled porosity address biofilm-mediated diseases and antibiotic resistance by adsorbing virulence factors and antimicrobial resistance genes, offering an effective alternative to conventional antibiotics.

WO2026234114A1PCT designated stage Publication Date: 2026-11-12UCL BUSINESS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063138
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Biofilm-mediated diseases and antibiotic resistance are difficult to treat due to the protective extracellular matrix and antibiotic inefficacy against slower-growing bacteria, exacerbated by antibiotic misuse, leading to increased antimicrobial resistance and surgical infection risks.

Method used

Porous carbon particles with controlled porosity, comprising micropores and meso/small macropores, are administered to prevent or treat biofilm-mediated diseases and antibiotic resistance by adsorbing virulence factors and antimicrobial resistance genes, without exerting selective pressure.

Benefits of technology

The porous carbon particles effectively reduce virulence factors and antimicrobial resistance genes, providing an alternative strategy to conventional antibiotics, thereby treating biofilm-mediated diseases and preventing antibiotic resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000053_0001_TABLE
    Figure IMGF000053_0001_TABLE
  • Figure IMGF000054_0001_TABLE
    Figure IMGF000054_0001_TABLE
  • Figure 00000055_0000
    Figure 00000055_0000
Patent Text Reader

Abstract

The invention relates to the treatment or prevention of biofilm-mediated disease using porous carbon particles. The invention also relates to the treatment or prevention of antibiotic resistance using porous carbon particles. The porous carbon particles comprise micropores of diameter (2) nm or less and meso pores / small macropores of diameter (30) nm to (500) nm, but substantially no mesopores of diameter greater than (2) nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] THERAPY

[0002] Field of the invention

[0003] The invention relates to the treatment or prevention of a biofilm-mediated disease using porous carbon particles. The invention also relates to the treatment or prevention of antibiotic resistance using porous carbon particles. The porous carbon particles comprise micropores of diameter 2 nm or less and meso pores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm. The invention also relates to methods for the treatment or prevention of a biofilm-mediated disease, using such porous carbon particles. The invention also relates to methods for the treatment or prevention of antibiotic resistance, using such porous carbon particles.

[0004] Background to the invention

[0005] Many disease states are associated with biofilm formation or disruption.

[0006] Biofilms are formed from multiple microorganisms embedded in a self-produced extracellular matrix. Biofilm formation plays a crucial role in pathogenesis, allowing bacteria to adhere to surfaces. The extracellular matrix provides protection against the immune system and antibiotics, making infections involving pathogenic biofilms difficult to treat.

[0007] The large intestine in mammals is typically coated with a biofilm. Depending on the composition of the biofilm, the biofilm may be beneficial or harmful to the host. Beneficial biofilms form a protective layer on the intestinal lining, aiding nutrient absorption and preventing colonisation of pathogenic bacteria. If the biofilm in the gut is disrupted or modified, for instance by antibiotics, or by the presence of pathogens, pathogenic bacterial may establish biofilms on the intestinal lining.

[0008] Pathogenic biofilm production is also the basis for a number of other diseases, including diseases of the mouth such as periodontitis, and infections elsewhere in the body such as urinary tract infections. Once established, diseases associated with biofilm formation can be very difficult to treat, as the pathogens within the biofilm are protected by the extracellular matrix. Also, antibiotics, which are most effective against rapidly dividing cells are less effective against the slower growing bacteria in biofilms. Further, conditions within biofilms can help to promote antibiotic resistance.Antibiotic resistance arises due to natural mutations, but has been accelerated by the overuse and misuse of antibiotics around the world. Antimicrobial resistance genes (ARGs) pose a significant concern when carried by pathogenic bacterial strains.

[0009] Without addressing the issue of antibiotic resistance, routine surgical procedures will carry a much higher risk of serious infection. The risk of serious infection for those with suppressed immune systems, such as those undergoing treatment for cancer, will also increase.

[0010] Orally administered adsorbent porous carbon particles have been used for centuries for the treatment or prevention of various disorders without any major side effects. Activated carbons are widely used to treat poisoning. A microporous carbon, AST-120 (available under the trade name KREMEZIN® from Kureha Corp., Japan) is used to treat patients with renal failure. However clinical trials evaluating the efficacy of AST-120 in the management of hepatic encephalopathy have proven negative.

[0011] WO 2013 / 136094 discloses the use of carbon particles with a bimodal pore size distribution in the treatment of liver disease.

[0012] WO 2024 / 261472 discloses the use of carbon particles with a bimodal pore size distribution in the treatment of a disease by modulating the microbiome of the gut.

[0013] Summary of the invention

[0014] The invention relates to the treatment or prevention of a biofilm-mediated disease. The invention also relates to a method of preventing or treating antibiotic resistance.

[0015] Accordingly the invention provides porous carbon particles for use in a method of preventing or treating a biofilm-mediated disease, wherein said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm, and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said biofilm-mediated disease.

[0016] The invention also provides porous carbon particles for use in a method of preventing or treating antibiotic resistance, wherein said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm; and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

[0017] The invention also provides a method of treating or preventing a biofilm-mediated disease, the method comprising administering porous carbon particles as described herein to a subject in need thereof, thereby preventing or treating said biofilm-mediated disease.

[0018] The invention also provides a method of treating or preventing antibiotic resistance, the method comprising administering porous carbon particles as described herein to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

[0019] The invention also provides use of such porous carbon particles in the manufacture of a medicament for treating or preventing a biofilm-mediated disease.

[0020] The invention also provides use of such porous carbon particles in the manufacture of a medicament for treating or preventing antibiotic resistance.

[0021] Brief description of the drawings

[0022] Figure 1: Pore distribution for phenolic resin derived carbons as measured by nitrogen adsorption and determined using BJH method for TE9 carbons unactivated to activated to 29 and 47% bum off. Activation primarily increases the pores in the micropore (<2nm diameter). The small macropores (50-500nm) are largely unaltered with no introduction of pores in the 2-50nm range (mesopores).

[0023] Figure 2: Representative pore size distribution of porous carbon particles of the invention, measured by Mercury porosimetry (A: TE7 test carbon; B: TE8 test carbon). The larger peak at above 30,000 is due to the voids between the carbon particles and not to porosity.

[0024] Figure 3: Increase in the macropore volume (50-500nm) with the increase in the pore former concentration from TE3 to TE7 for carbon activated to approximately 50% bum off along. No significant introduction of pores in the mesopore range (2-50nm) or change in the pores in the micropore domain.

[0025] Figure 4: A Effect of degree of activation on the pore structure as determined by mercury porosimetry, evolution of pore volume on a cm3 / gm basis and reduction in bulk density caused by activation; B Effect of degree of activation on pore structure asdetermined by mercury Porosimetry, change in the mercury pore volume in cm3 / cm3 as a function of activation extent.

[0026] Figure 5: Experimental design and Serum Biomarkers improving after Carbalive treatment. A) experimental design. B) Serum biomarkers showing improvement in Lactulose / L-Rhamnose ratio with Carbalive treatment (p values <0.5), the boxplots show the the Log2 -fold-change in week 4 and week 12 in relation to baseline in Active and Placebo groups, Statistical significance was assessed using two-sided Mann-Whitney U-test.

[0027] Figure 6: Effect of Carbalive treatment on Microbiome species and functions. A) Boxplot showing species richness in active and placebo arms at baseline, week 4 and week 12. No statistically significant difference was observed between active and placebo groups; B) Boxplots show Beta diversity distance between time points within the same individual comparing Active vs Placebo groups. No statistically significant difference was observed between active and placebo groups; C) Differentially Abundant (pangenome) species between active and placebo Arms, the heatmap shows the log2-fold change in mean values of species abundance between Active and Placebo arms; D) The cladogram shows the KEGG functional categories with at least three genes increasing or decreasing after Carbalive treatment, external ring shows the number of genes increasing (red) or decreasing (blue). Stars in C mark p values < 0.05. Statistical significance was assessed using two-sided Mann-Whitney U-test.

[0028] Figure 7: Virulence Factors decreasing after Carbalive treatment. A) Heatmap showing the log2-fold change in mean values Virulence Factors between Active and Placebo, stars (*) mark p values < 0.05; B). The boxplots show the sum of the abundance values of all differentially abundant virulence factors in Active and Placebo groups. C) Alluvial plots show the proportions of the mean abundance values of the Virulence Factors genes and their associated family of samples at week 12 in the active (left) and placebo arm (right). D) Correlation network between VF genes and measured Serum Biomarkers: Oval nodes represent genes with virulence factor annotations within a Species (MSP). Rectangle nodes represent the measured Serum Biomarkers; Edges represent correlations between a gene and a Biomarkers; positive correlations are shown in red, negative correlations in blue; edge width is proportional to absolute correlation value. Only correlations with p values < 0.002 are shown. Statistical significance in A) was assessed using two-sided Mann-Whitney U-test. Correlations in D) were calculated using Spearman correlation test.Figure 8: Antibiotic Resistance Genes decreasing after Carbalive treatment. A) Heatmap showing the log2-fold change in mean values predicted Antibiotic Resistant Genes between Active and Placebo, stars (*) mark p values < 0.05; B) The boxplots show the sum of the abundance values of all differentially abundant Antibiotic Resistance Genes in Active and Placebo groups. C) Alluvial plots show the proportions of the mean abundance values of the Virulence Factors genes and their associated family of samples at week 12 in the active (left) and placebo arm (right).

[0029] Figure 9: CONSORT for trial - assignment of patients into Active and Placebo groups.

[0030] Figure 10: Serum Biomarkers. Log2 Fold Change after 4 and 12 weeks in

[0031] relation to baseline of Serum Biomarkers in Active and Placebo Groups, a, Systemic Inflammation b, Gut Permeability, c, Intestine, Kidney and Endothelial function, d, Metabolism, e, Nutrition, f, Cell Death. Stars show p-value <0.5 , Mann-Whitney U-test, alternative = less, comparing with the other arm at the same week.

[0032] Figure 11: Fecal Biomarkers. Log2 Fold Change after 4 and 12 weeks in relation to baseline of Fecal Biomarkers in Active and Placebo Groups. Stars show p-value <0.5 , Mann-Whitney U-test, alternative = less, comparing with the other arm at the same week.

[0033] Figure 12: Secondary Bile Acids. Log2 Fold Change after 4 and 12 weeks

[0034] in relation to baseline of Secondary Bile Acids, in Active and Placebo Groups, a, Secondary Bile acids measured in serum samples, b, Secondary Bile acids measured in fecal samples. Stars show p-value <0.5, Mann-Whitney U-test, alternative = less, comparing with the other arm at the same week.

[0035] Figure 13: Targeted Metabolomics. Log2 Fold Change after 4 and 12 weeks in relation to baseline of Targeted Metabolomic measured metabolites in Active and Placebo Groups. Stars show p-value <0.5, Mann-Whitney U-test, alternative = less, comparing with the other arm at the same week.

[0036] Figure 14: Possible mechanism of action of CARBALIVE particles.

[0037] Detailed description of the invention

[0038] Throughout this specification, the word “comprise”, or variations such as “comprised” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.As used herein the term “carbon particle of controlled porosity” is equivalent to “porous carbon particle”.

[0039] As used herein, the term “micropore” refers to pores with diameter of 2 nm or less, as measured by nitrogen adsorption and mercury porosimetry methods and as defined by IUPAC.

[0040] As used herein, the term “mesopore” refers to pores with diameter of greater than 2 nm and less than 50 nm, as measured by nitrogen adsorption and mercury porosimetry methods and as defined by IUPAC.

[0041] As used herein, the term “macropore” refers to pores with diameter of 50 nm or more, as measured by nitrogen adsorption and mercury porosimetry methods and as defined by IUPAC.

[0042] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that that prior art forms part of the general knowledge.

[0043] As used herein, the term “biofilm” would be well understood by the skilled person. Typically, the term “biofilm” refers to a community of one or more microorganisms (bacteria, archaea, protozoa, fungi, algae etc.) where the cells are adhered to each other, and often also a solid surface. The organisms within the biofilm produce and are embedded within an extracellular matrix, composed of components such as polysaccharides, proteins, lipids and DNA. The microorganisms in the biofilm are distinct from planktonic cells of the same organism and may undergo a phenotypic shift in behaviour, giving rise to changes in cell morphology, metabolic rate, changes in nutrient uptake etc compared to their planktonic counterparts.

[0044] As used herein, the term “biofilm-mediated disease” refers to any disease caused by or associated with a biofilm. Biofilm-mediated diseases can be very difficult to treat as the microorganisms within the biofilm can evade the immune response and be highly resistant to conventional antimicrobial treatments.

[0045] During biofilm formation, various genetic changes occur in the microorganisms involved, usually in relation to genes associated with attachment, adhesion, matrix production and survival within the biofilm environment. Virulence factors (VFs) are components imparting pathogens, such as pathogenic bacteria, with an increased capacity to infect a host organism, for instance factors which improve a pathogen’s ability to invade, multiply or harm a host. Some virulence factors are associated with biofilm formation. For example, adhesion virulence factors enable bacterial attachmentto surfaces, invasion and biofilm formation. Fibronectin binding protein (FBP) promotes fibronectin-mediated collagen recruitment, which leads to matrix deposition on and between streptococcal cells to induce the formation of large bacterial aggregates. Nutritional virulence factors include genes related to metal ion uptake, like psaA, whose key function is the transport of Mn2+ and Zn2+ into the cytoplasm of the bacteria; psaA mutants show marked impact on the capacity to colonize and increased susceptibility to oxidative damage. The present inventors have investigated the effects of porous carbon particles on the gut microbiome and biomarkers of patients suffering from cirrhosis. Cirrhosis patients typically experience gut-derived endotoxaemia and bacterial translocation, which can be caused by pathogenic biofilms. Hence, treatments found to reduce markers of biofilms in such patients would also be useful for treating other biofilm-mediated diseases, which would also be associated increases in virulence factors relevant to biofilm formation, such as adhesion virulence factors.

[0046] The present inventors have surprisingly discovered that porous carbon particles as described herein are able to decrease virulence factor genes in the microbiome which are specifically associated with biofilm formation. For instance, exposure to porous carbon particles decreases the presence of genes associated with adhesion and nutrition (see Figures 6D and 7D). This paves the way for new methods for addressing biofilm-mediated disease, overcoming the current limitations of antibiotic treatment in treating pathogenic biofilms.

[0047] Further, the present inventors have also found that porous carbon particles as described herein decrease genes in the microbiome associated with antibiotic resistance. Antimicrobial resistance genes (ARGs) confer microbial communities with the ability to resist antibiotics and represent quorum-sensing and secretion systems that allow microbiota to survive through adaptations in genotypic responses to antimicrobials e.g. antibiotics. The inventors unexpectedly discovered a marked reduction in the abundance of ARGs in microbiomes of the group treated with porous carbon particles compared to the placebo group. Decreases of ARGs associated with resistance to several antibiotics including beta lactams (e.g. PBPla and PBPlb, CfxA3, a class A beta-lactamase), aminoglycosides (e.g. CfxA3), MLS (e.g. VGAC) and multidrug resistance genes (e.g. RamA and oqxB) were observed (see Figure 8A). This discovery therefore provides an alternative strategy for addressing antibiotic resistance, separate to the “arms race” between antibiotic development and bacterial antibiotic resistance.In one aspect, therefore, the invention relates to porous carbon particles for use in a method of preventing or treating a biofilm-mediated disease, wherein said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm, and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating the biofilm-mediated disease.

[0048] In another aspect, the invention relates to porous carbon particles for use in a method of preventing or treating antibiotic resistance, wherein said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm, and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

[0049] The present inventors have found that such non absorbable porous carbon particles having a controlled porosity to provide a relatively high proportion of pores in the meso-to-macroporous range, or in the micro- and small macro ranges, confer a high adsorptive capacity for larger biologically relevant molecules such as bacterial toxins in addition to smaller intraluminal targets. These porous carbon particles may act to prevent biofilm formation by binding to and selectively decreasing the abundance of virulent species without exerting selective pressure (as is the case with antibiotic administration, which in the long run increases the risk of infection of resistant strains -see Figure 14).

[0050] Conventionally produced activated carbon (e.g. granular activated carbon) is normally microporous, having pores of diameter less than 2 nm (IUPAC definition), with little or no pore volume in the mesopore (2-50 nm) or macropore (greater than 50 nm) range.

[0051] The porous carbon particles for use in the present invention may have 20% to 90% of the total pore volume made up of pores having a mean diameter of 2 nm or less (micropores), and 75% or more of the remainder of the total pore volume (i.e. the pore volume made up of pores having a mean diameter greater than 2 nm) is made up of pores having a mean diameter of from 30 nm to 500 nm (mesopores / small macropores).Thus, the porous carbon particles may have a bimodal distribution of pore sizes whereby the total pore volume is distributed between the micropore and large mesopore / small macropore ranges, with substantially no mesopores of diameter greater than 2 nm and less than 30nm or large macropores of diameter greater than 500 nm. The presence of large macropores is preferably minimised as pores of mean diameter above 500 nm will reduce the physical strength of the particles and provide little or no improvement in adsorption.

[0052] Typically, mesopores of diameter greater than 2 nm and less than 30 nm make up 20% of the total pore volume or less, more preferably 15% or less, still more preferably 10% or less. Typically, large macropores of diameter greater than 500 nm make up 20% of the total pore volume or less, more preferably 15% or less, still more preferably 10% or less. Typically, mesopores of diameter greater than 2 nm and less than 30 nm, and large macropores of diameter greater than 500 nm together make up 20% of the total pore volume or less, preferably 15% or less, more preferably 10% or less.

[0053] Typically, 25% to 70%, preferably 35% to 60%, more preferably 45% to 55% of the total pore volume is made up of pores having a mean diameter of 2 nm or less.

[0054] Typically, 80% or more, preferably 85% or more, more preferably 90% or more of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm, preferably 30 nm to 300 nm, more preferably 50 to 200 nm.

[0055] Typically, the total pore volume as measured by nitrogen adsorption is from 0.5 to 2.5 cm3g'1, preferably 1.0 to 2.0 cm3g'1, more preferably 1.2 to 1.8 cm3g'1. In one embodiment the total pore volume as measured by nitrogen adsorption is 1.3 to 1.8 cm3g'1. In one embodiment the total pore volume as measured by nitrogen adsorption is 1.3 to 1.4 cm3g'1.

[0056] Typically, the pore volume attributable to micropores having a mean diameter of 2 nm or less is 0.2 cm3g'1or more, preferably 0.2 to 0.5 cm3g'1, more preferably 0.3 to 0.4 cm3g'1.

[0057] Typically, the bulk density of the porous carbon particles is 0.10 gem'3or more, preferably 0.15 gem'3or more, more preferably 0.20 gem'3or more. Particles having a higher bulk density result in a reduced overall volume of carbon required for oral administration, which is beneficial e.g. for patient compliance. In one embodiment the bulk density of the porous carbon particles is 0.10 gem'3to 0.30 gem'3, preferably 0.15 gem'3to 0.25 gem'3, more preferably 0.18 gem'3to 0.22 gem'3.In contrast, in one embodiment, in the porous carbon at least 20% of the total pore volume is made up of pores having a mean diameter of from 2 to 200 nm.

[0058] Preferably, at least 20% of the total pore volume of the porous carbon particles is made up of pores having a mean diameter of from 20 to 200 nm, preferably from 30 to 200 nm, preferably from 30 to 150 nm, more preferably from 50 to 120 nm, or from 60 to 100 nm. The contribution of pores of these sizes to the total pore volume is preferably greater than 25%, more preferably greater than 30%. Suitably, pores of the aforementioned sizes make up from 25 to 75% of the total pore volume, preferably from 30 to 60%, preferably 30 to 50%, more preferably 30 to 40% of the total pore volume.

[0059] The porous carbon particles for use in the present invention may also comprise micropores having a mean diameter of from 0.6 to 2 nm. The contribution of such micropores to the total pore volume may be up to 50%, for example from 5 to 30%.

[0060] The porous carbon particles may also comprise larger macropores, having a diameter of greater than 200 nm, for example greater than 500 nm. The contribution of such macropores having a diameter of greater than 200 nm to the total pore volume may be up to 74%, for example from 25 to 70%.

[0061] Preferably, the total volume of pores having a mean diameter of from 30 to 150 nm is from 0.2 to 2.0 cm3 / g, preferably 0.5 to 1.5 cm3 / g.

[0062] When the particles additionally comprise micropores, the total volume of micropores having a mean diameter of from 0.6 to 2 nm is preferably from 0.01 to 1.5cm3 / g.

[0063] When the particles additionally comprise larger macropores, the total volume of macropores having a mean diameter of greater than 200 nm is preferably from 0.2 to 2.0 cm3 / g, preferably from 0.2 to 1.0 cm3 / g.

[0064] In one particularly preferred embodiment the porous carbon particles for use in the present invention have the properties set out below.

[0065] • Micropore Pore size 0.5-2nm

[0066] • BET surface area 700 to 2000, preferably 1000-1500m2 / g

[0067] • Micropore Pore volume 0.1 to 1.1 cm3 / g, preferably 0.3 to 1.0cm3 / g • Meso / small macropore size 30-500nm, preferably 50-300nm

[0068] • meso / small macropore volume 0.8 to 2.5cm3 / g

[0069] • Total pore volume 0.9 to 3.5 cm3 / g, preferably 1.1 to 2.0 cm3 / g • Proportion of micropores (%volume) 27% to 29%In one embodiment, the porous carbon particles for use according to the present invention have at least 20% of the total pore volume of the porous carbon particles made up of pores having a mean diameter of from 20 to 200 nm, and 20% to 90% of the total pore volume is made up of pores having a mean diameter of 2 nm or less, but less than 75% of the remainder of the total pore volume is made up of pores having a mean diameter of from 30 nm to 500 nm.

[0070] In one embodiment, the porous carbon particles for use in the present invention have 20% to 90% of the total pore volume made up of pores having a mean diameter of 2 nm or less, and 75% or more of the remainder of the total pore volume made up of pores having a mean diameter of from 30 nm to 500 nm, but at least 80% of the total pore volume of the porous carbon particles made up of pores which do not have a mean diameter of from 20 to 200 nm.

[0071] Carbon porosity can be measured using mercury porosimetry (e.g. using an automatic mercury intrusion porosimeter such as the PoreMaster® mercury intrusion porosimeter (Quantachrome Instruments)) and / or gas sorption analysis (e.g. using an Autosorb gas sorption analyser (Quantachrome Instruments)).

[0072] Mercury porosimetry measures pores greater than 2 nm, particularly greater than 20 nm, and gas sorption analysis is used to measure micropores and mesopores and generally provides an effective measure of porosity for pores having a mean diameter of 0.5 nm to 50 nm, and so it may be necessary to use both methods, especially to measure particles having bimodal porosity as described above. Above 50 nm results obtained by the nitrogen technique may not agree with those obtained by the mercury techniques. In the case of a discrepancy in results for pores of mean diameter greater than 50 nm, the results obtained by mercury should be used.

[0073] Figure 2 shows a measure of the pore volume in the larger, small macropores of particles according to the present invention as provided by mercury porosimetry.

[0074] Micropores are not visible in Figure 2 because mercury porosimetry measures pores greater than 2 nm. Figure 1 shows the evolution of the nitrogen pore volume in the <2 nm and 50-500 nm pore range for the TE7 carbon as a function of bum off (degree of activation).

[0075] The change in mercury pore volume with activation is shown in Figure 4. When the mercury pore volume is reported on a cm3gm'1basis there is an apparent large increase in pore volume with activation. However, this primarily reflects the density decrease with activation. On a volume basis, which is a better reflection of the structurechange, the small macropore volume remains constant for all levels of activation, i.e. only the micropore volume is enhanced by activation.

[0076] Results obtained by mercury porosimetry may show results at higher pore diameters which correspond to voids between porous carbon particles, and do not reflect the size of pores within the carbon particles. Thus, there will be an effective macropore volume equivalent to -35% of the volume of the beads attributable to voids, where the void size is -20% of the bead size. Mercury porosimetry results of 15% of bead size or more, e.g. 20% of bead size or more, can therefore be disregarded when considering porosity. For example, carbon particles of 250-500 pm in size may have an interparticle void size reflected in the mercury data of around 50-100 pm.

[0077] Typically, the large mesopore / small macropore volume on a weight basis, determined by mercury porosimetry is 0.60 cm3gm’1, preferably higher than 1.1 cm3gm'1and more preferably higher than 1.5 cm3gm'1.

[0078] The gas sorption analysis technique used to measure micropores is typically nitrogen sorption analysis.

[0079] The micro pores in the carbons can be increased by activation and the change in surface area and pore volume with activation is shown in table 2. Preferably, the porous carbon particles have a specific surface area as measured by a BET (Brunauer-Emmett-Teller) method of at least 700 m2 / g. The specific surface area may be in excess of 900 m2 / g, typically in excess of 1000 m2 / g. In one embodiment the specific surface area is over 1200 m2 / g. Suitable specific surface areas are in the range of 1000 to 2500 m2 / g, preferably 1400 to 2000 m2 / g. In one embodiment the specific surface area is from 700 m2 / g to 2000 m2 / g, typically 900 m2 / g to 1400 m2 / g, preferably 1000 m2 / g to 1200 m2 / g. In another embodiment the specific surface area is 1200 m2 / g or less, e.g. 700 to 1200 m2 / g, 900 to 1200 m2 / g or 1000 to 1200 m2 / g.

[0080] Preferably, the porous carbon particles have a mean diameter of from 2 to 2000 pm, for example from 50 to 2000 pm, from 200 to 1600 pm, or from 100 to 1000 pm. Suitable particles may thus have a mean diameter of, for example, from 200 to 600 pm, preferably 250 to 500 pm. Other suitable particles may have mean diameters of 1000 to 2000 pm, preferably 1000 to 1500 pm. However, particles having a mean diameter of 1000 pm or less are preferred. The particle size can be measured using laser diffraction (e.g. using a Malvern particle sizer (Malvern Instruments)).

[0081] Preferably, the porous carbon particles are in the form of spherical particles.In one embodiment, the porous carbon particles may be surface-modified in order to alter their adsorption capacity for biological molecules.

[0082] The porous carbon particles may be in the form of uncoated particles. Such uncoated porous carbon particles have proven biocompatibility. Alternatively, the particles may be coated in order to control their release and adsorption properties. For example, the particles may be coated with a film that will allow predominant release into the large bowel.

[0083] The porous carbon particles for use in the present invention may be produced by any suitable method. Suitable methods are described, for example in WO 02 / 12380.

[0084] Preparation of Phenolic Resin Derived Spherical Carbon Beads with Bimodal Porosity

[0085] In relation to this invention there are two types of macropores. In macroporous beads they are located within beads and formed by pore-formers. Their size is typically 30-500nm, preferably 50 - 300 nm

[0086] Typically a precursor resin formulation is used which comprises a significant proportion of pore former, e.g. 250 parts ethylene glycol or other pore former to 100 parts of resin-forming components although high porosity can also be achieved through the use of additives such as urea in combination with the ethylene glycol.

[0087] US2008025907A1 (Tennison et al.,) the disclosure of which is incorporated herein by reference) discloses making a mesoporous resin by condensing a nucleophilic component which comprises a phenolic compound or a phenol condensation prepolymer with at least one electrophilic cross-linking agent selected from formaldehyde, paraformaldehyde, furfural and hexamethylene tetramine in the presence of a pore-former selected from the group consisting of a diol (e.g. ethylene glycol), a diol ether, a cyclic ester, a substituted cyclic ester, a substituted linear amide, a substituted cyclic amide, an amino alcohol and a mixture of any of the above with water to form a resin. The pore-former is present in an amount effective to impart macroporosity to the resin (e.g. at least 150 parts by weight of the pore former being used to dissolve 100 parts by weight of the total resin forming components, i.e. nucleophilic component plus electrophilic component), and it is removed from the porous resin after condensation by cascade washing with water or by vacuum drying.

[0088] The resulting resin may be carbonised by heating in an inert atmosphere to a temperature of at least 600°C to give a material having a bimodal distribution of pores,the pore structure as estimated by nitrogen adsorption comprising micropores and mesopores or macropores. The value for the differential of pore volume with respect to the logarithm of pore radius (dV / dlogR) for the mesopores is greater than 0.2 for at least some values of pore size in the range 20-500 A. The mesoporous carbon may have a BET surface area of 250-700m2 / g without activation. It may be activated by heating it at high temperature in the presence of carbon dioxide, steam or a mixture thereof, e.g. by heating it in carbon dioxide at above 800°C. It may then have surface areas of up to 2000 m2 / g and even higher e.g. 1000-2000m2 / g. As used herein the term "BET surface area" is determined by the Brunauer, Emmett, and Teller (BET) method according to ASTM D1993-91, see also ASTM D6556-04. For the purposes of the current invention it is preferred to use carbon dioxide.

[0089] Phenolic resins - nucleophilic component

[0090] Resins for making carbonaceous material can be prepared from any of the starting materials disclosed in US2008025907A1. Nucleophilic components may comprise phenol, bisphenol A, alkyl phenols e.g. cresol, diphenols e.g. resorcinol and hydroquinone and aminophenols e.g. m-amino-phenol.

[0091] It is preferred to use as nucleophilic component a phenolic novolac or other similar oligomeric starting material which because it is already partly polymerized makes polymerization to the desired resin a less exothermic and hence more controllable reaction. The preferred novolacs have average molecular weights (AMW) in the range of from 300 to 3000 prior to cross-linking (corresponding to a DP with respect to phenol of about 3-30). Where novolac resins are used, they may be solids with melting points in the region of 100°C. Novolac resins of MW less than 2000 and preferably less than 1500 form crosslinked resins which on carbonisation tend to produce carbons with desired pore size distributions using lower amounts of pore former. Novolacs are thermally stable in that they can be heated so that they become molten and cooled so that they solidify repeatedly without structural change. They are cured on addition of cross-linking agents and heating. Fully cured resins are infusible and insoluble.

[0092] Whilst commercial novolacs are largely produced using phenol and formaldehyde, a variety of modifying reagents can be used at the pre-polymer formation stage to introduce a range of different oxygen and nitrogen functionalities and crosslinking sites. These include but are not limited to: -(a) Dihydric phenols e.g. resorcinol and hydroquinone. Both are more reactive than phenol and can lead to some cross-linking at the pre-polymer production stage. It is also possible to introduce these compounds at the cross-linking stage to provide different cross-linking paths. These also increase the oxygen functionality of the resins.

[0093] (b) Nitrogen containing compounds that are active in polycondensation reactions, such as urea, aromatic (aniline, m-amino phenol) and heteroaromatic (melamine) amines. These allow the introduction of specific types of nitrogen functionality into the initial polymer and final carbon and influence the development of the mesoporous structure of both the resins and the final carbons. Like hydroquinone and resorcinol, all the nitrogen containing nucleophilic modifying reagents which can be used possess two or more active sites and are more reactive in condensation reactions than phenol or novolacs. It means that they are first to react with primary cross-linking agents forming secondary cross-linking agents in situ.

[0094] The nucleophilic component may be provided alone or in association with a polymerization catalyst which may be a weak organic acid miscible with the novolac and / or soluble in the pore former e.g. salicylic acid, oxalic acid or phthalic acid. Whilst these can be used in the current invention the use of phenol alone preferred to minimise the concentration of more hydrophilic sites.

[0095] The concentration of novolac in the pore former may be such that when combined with the solution of cross-linking agent in the same pore former the overall weight ratio of pore former to (novolac + cross-linking agent) is at least 150: 100 by weight. The actual ratios of novolac:pore former and cross-linking agent:pore former are set according to convenience in operation e.g. in the case of the process disclosed in WO 2008 / 043983 (Tennison) by the operational requirements of a bead production plant and are controlled by the viscosity of the novolac:pore former solution such that it remains pumpable and by the ratio of cross-linking agent:pore former such that the cross-linking agent remains in solution throughout the plant

[0096] Cross-linking agents for phenolic resins

[0097] The cross-linking agent is normally used in an amount of from 5 to 40 parts by weight (pbw) per 100 parts by weight of the nucleophilic components e.g. novolac,. It may be, for example, an aldehyde e.g. formaldehyde or furfural, it could be hexamethylenetetramine (hexamine), or hydroxymethylated melamine.Hexamine is preferably used as cross-linking agent. It is preferably used for cross-linking novolac resin at a proportion of 10 to 25 pbw e.g. about 15 to 20 pbw hexamine per 100 pbw of novolac. This ensures formation of the solid resin with maximal cross-linking degree and ensures the stability of the macropore structure during subsequent removal of the pore former

[0098] Pore-formers

[0099] The pore former also acts as solvent. Thus, the pore former is preferably used in sufficient quantities to dissolve the components of the resin system, the weight ratio of pore former to the total components of the resin system resin being preferably at least 1.5:1. Below this level the resulting resins have essentially no macroporosity.

[0100] Details of suitable pore formers are given in US2008025907A1 (Tennison). The pore former may be, for example, a diol, a diol-ether, a cyclic ester, a substituted cyclic or linear amide or an amino alcohol e.g. ethylene glycol, 1,4-butylene glycol, di ethylene glycol, triethylene glycol, y-butyrolactone, propylene carbonate, dimethylformamide, N-methyl-2-pyrrolidinone and monoethanolamine, ethylene glycol being preferred, and where the selection is also limited by the thermal properties of the solvent as it should not boil or have an excessive vapour pressure at the temperatures used in the curing process.

[0101] It is thought that the mechanism of meso- and macropore generation is due to a phase separation process that occurs during the cross-linking reaction. In the absence of a pore former, as the linear chains of pre-polymer undergo cross-linking, their molecular weight initially increases. Residual low molecular weight components become insoluble in the higher molecular weight regions causing a phase separation into cross-linked high molecular weight domains within the lower molecular weight continuous phase. Further condensation of light components to the outside of the growing domains occurs until the cross-linked phase becomes essentially continuous with residual lower molecular weight pre-polymer trapped between the domains. In the presence of a low level of pore former the pore former is compatible with, and remains within, the cross-linked resin domains, (e.g., <120 parts / 100 parts Novolac for the Novolac-Hexamine-Ethylene Glycol reaction system), whilst the remainder forms a solution with the partially cross-linked polymer between the domains. In the presence of higher levels of pore former, which exceed the capacity of the cross-linked resin, the pore former adds to the low MW polymer fraction increasing the volume of material inthe voids between the domains that gives rise to the mesoporosity and / or macroporosity. In general, the higher the pore former content, the wider the mesopores, up to macropores, and the higher the pore volume.

[0102] This phase separation mechanism provides a variety of ways of controlling the pore development in the cross-linked resin structures. These include chemical composition and concentration of the pore former; chemical composition and quantity of the cross-linking electrophilic agents, presence, chemical nature and concentration of modifying nucleophilic agents, chemical composition of phenolic nucleophilic components (phenol, novolac), the presence of water within the solvent and concentration of any curing catalyst if present.

[0103] Production of resin precursor and carbon in bead form

[0104] In US2008025907A1, production of the resin in both powder and bead form is disclosed. Production of the bead form may be by pouring a solution of a partially cross-linked pre-polymer into a hot liquid such as mineral oil containing a dispersing agent and stirring the mixture. The pre-polymer solution forms into beads which are initially liquid and then, as curing proceeds, become solid. The average bead particle size is controlled by several process parameters including the stirrer type and speed, the oil temperature and viscosity, the pre-polymer solution viscosity and volume ratio of the solution to the oil and the mean size can be adjusted between 5 and 2000pm. The beads can then be filtered off from the oil. In a preparative example, industrial novolac resin is mixed with ethylene glycol at an elevated temperature, mixed with hexamine and heated to give a viscous solution which is poured into mineral oil containing a drying oil, after which the mixture is further heated to effect curing. On completion of curing, the reaction mixture is cooled, after which the resulting porous resin is filtered off, and washed with hot water to remove pore former. The cured beads are carbonized to porous carbon beads which have a pore structure as indicated above, and may be activated as indicated above. The beads can be produced with a narrow particle size distribution e.g. with a D90:D10 of better than 10 and preferably better than 5.

[0105] US2010 / 0086469 Al (Tennison) describes and claims a process for producing discrete solid beads of polymeric material e.g. phenolic resin having a porous structure, which process may produce resin beads on an industrial scale without aggregates of resin building up speedily and interrupting production. The process comprises the steps of: (a) combining a stream of a polymerizable liquid precursor e.g. a novolac andhexamine as cross-linking agent dissolved in a first polar organic liquid e.g. ethylene glycol with a stream of a liquid suspension medium which is a second non-polar organic liquid with which the liquid precursor is substantially or completely immiscible e.g. transformer oil containing a drying oil; (b) mixing the combined stream to disperse the polymerizable liquid precursor as droplets in the suspension medium e.g. using an inline static mixer; (c) allowing the droplets to polymerise in a laminar flow of the suspension medium so as to form discrete solid beads that cannot agglomerate; and (d) recovering the beads from the suspension medium.

[0106] Dispersion medium

[0107] For bead production, the pore former comprises a polar organic liquid e.g. ethylene glycol chosen in combination with dispersion medium which is a non-polar organic liquid so as to form a mainly or wholly immiscible combination, the greater the incompatibility between the pore former which forms the dispersed phase and the dispersion medium, the less pore former becomes extracted into the dispersion medium. The pore former desirably has a greater density than the dispersion medium with which it is intended to be used so that droplets of the pore former containing dissolved resinforming components will pass down a column more rapidly than a descending flow of dispersion medium therein. Both protic and aprotic solvents of different classes of organic compounds match these requirements and can be used as pore formers, both individually and in mixtures. In addition to dissolving the reactive components and any catalyst, the pore former should also, in the case of phenolic resins, be compatible with water and / or other minor condensation products (e.g. ammonia) which are formed by elimination as polymerization proceeds, and the pore former is preferably highly miscible with water so that it can be readily removed from the polymerized resin beads by washing.

[0108] The dispersion medium is a liquid which can be heated to the temperature at which curing is carried out e.g. to 160°C without boiling at ambient pressure and without decomposition and which is immiscible with ethylene glycol and with the dissolved components therein. It may be hydrocarbon-based transformer oil which is a refined mineral oil and is a by-product of the distillation of petroleum. It may be composed principally of C15-C40 alkanes and cycloalkanes, have a density of 0.8-0.9 depending upon grade and have a boiling point at ambient pressure of 260-330°C, also depending upon grade. Transformer oil has a viscosity of about 0.5 poise at 150°Cwhich is a typical cure temperature. Transformer oil or other dispersion medium may be used in volumes 3-10 times the volume of the combined streams of nucleophilic precursor and crosslinking agent e.g. about 5 times.

[0109] Dispersing agents

[0110] Preferred dispersing agents which are dissolved in the dispersion medium before that medium is contacted with the reaction mixture to be dispersed therein to retard droplet coalescence are either sold as drying oils e.g. Danish oil or are produced by partially oxidizing naturally occurring precursors such as tung oil, linseed oil etc. The dispersing agents are consumed as the process proceeds, so that if the dispersion medium is recycled, dispersing agent in the recycled oil stream should be replenished. The dispersing agent is conveniently supplied as a stream in solution in the dispersion medium e.g. transformer oil and e.g. in an amount of 5-10%v / v where Danish oil is used which contains a low concentration of the active component to give final concentration of the dispersant in the dispersion medium 0.2 - 1% v / v. Higher dispersant concentrations would be used in the case of oxidised vegetable oils.

[0111] Solvent Removal from resin beads and granular materials

[0112] The resin beads or granules formed as described above must first be treated to remove the pore former after which they can be carbonised and activated. The pore former can be removed either by water washing or vacuum drying. The beads can be treated directly . If water washing is used this preferably uses at least a two stage process using hot water at ~80C. This is preferably carried out using a cascade washing process where the water from the second stage, which contains a relatively low level of the pore former, is recycled to the first washing stage. The waste water from the first stage, which contains a high level of the pore former can either be disposed of or the pore former can be recovered by distillation. Vacuum drying can be carried out using any commercially available vacuum dryers although it is preferred that this should use a stirred or moving bed rather than a static tray system.

[0113] Carbonisation and Activation of Resin Structures

[0114] In US 2010 / 0098615A1 (Tennison, the disclosure of which is incorporated herein by reference) there is provided a process for carbonizing and activating bead or granular polymeric material and especially the solid beads of polymeric materialresulting from the process of US2010 / 0086469, which comprises supplying the material to an externally fired rotary kiln maintained at carbonizing and activating temperatures, the kiln having a downward slope to progress the material as it rotates, the kiln having an atmosphere free of oxygen provided by a counter-current of carbon dioxide or steam, and annular weirs being provided at intervals along the kiln to control progress of the material.

[0115] Alternatively the resin beads can be carbonised and activated on a smaller scale using a batch furnace. Here the carbonisation and activation may be carried out as separate steps where the carbonisation takes place in carbon dioxide at -800C and the activation in carbon dioxide at between 850 and 950C or in steam at between 700 and 850C.

[0116] For the purposes of this invention it is preferred to use carbon dioxide as the activating medium although it is also possible to use other media.

[0117] Use of Porous Carbon Particles in the Treatment of Disease

[0118] The porous carbon particles described above are useful in the treatment or prevention of a biofilm-mediated disease.

[0119] “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition and / or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition and / or preventing or delaying the spread of the disease or condition); and / or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life and / or prolonging survival).

[0120] “Prevention” or “preventing” means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop.

[0121] “Subject” refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. Incertain embodiments, the subject is a mammal. In certain embodiments, the subject is a human.

[0122] The treatment or prevention of a biofilm-mediated disease may include the prevention of biofilm formation, or the disruption and / or destructions of an existing pathogenic biofilm. The treatment or prevention of a biofilm-mediated disease may include preventing the disruption of beneficial biofilms.

[0123] Administration of the porous carbon particles described herein may reduce the expression of virulence factors. Typically, the administration of porous carbon particles described herein reduces the expression of virulence factors associated with biofilm formation. For instance, the administration of porous carbon particles described herein reduces the expression of adhesion-related virulence factors such asFibronectin binding protein (FBP). FBP promotes fibronectin-mediated collagen recruitment, which leads to matrix deposition on and between streptococcal cells to induce the formation of large bacterial aggregates. The administration of porous carbon particles described herein may reduce the expression of nutritional virulence factors, such as genes related to metal ion uptake, like psaA,psaA plays an important role in development of the extracellular matrix in biofilm formation.

[0124] Biofilm-mediated diseases may include those caused by pathogenic biofilms. Biofilm-mediated diseases may also include those caused by the disruption or destruction of a beneficial biofilm. Examples of diseases caused by pathogenic biofilms include infections, such as chronic infections, periodontitis, urinary tract infections and infective endocarditis.

[0125] Infections may also be caused by the ingestion of objects which comprise a biofilm. For instance, ingestion of particles comprising biofilms, such as microplastic particles, could cause disease. Ingestion of other substances comprising biofilms, such as contaminated water, could also cause disease.

[0126] Some disease states make the body more susceptible to biofilm formation. One example of this is cystic fibrosis, in which the body secrets a thick sticky mucus that can affect the lungs and digestive system. This mucus-rich environment can foster pathogenic biofilm growth, leading to persistent and difficult to treat lung infections.

[0127] Biofilms can also form on the surface of chronic wounds, thereby impeding healing, and potentially leading to further infections.

[0128] The biofilm-mediated disease may therefore be selected from an infection, a chronic infection, periodontitis, cystic fibrosis, urinary tract infection, infectiveendocarditis, a chronic wound or a disease resulting from ingestion of a substance or particle comprising a biofilm, e.g. a microplastic particle.

[0129] As discussed above, the porous carbon particles described herein reduce the presence of genes associated with antibiotic resistance. For instance, the inventors found a marked reduction in the abundance of ARGs in the group treated with porous carbon particles compared with the placebo group, with significant effects on ARGs associated with several antibiotics including beta lactams, aminoglycosides, macrolide, lincosamide and streptogramin (MLS) antibiotics and also multidrug resistance genes.

[0130] The porous carbon particles described herein may reduce the presence of genes associated with multidrug resistance, such as genes related to the efflux pump mechanism e.g. RamA and oqxB. The porous carbon particles described herein may reduce the presence of genes associated with beta-lactam resistance, such as PBPla, PBPlb and CfxA3. The porous carbon particles described herein may reduce the presence of genes associated with aminoglycoside resistance. The antibiotic resistance may therefore be multidrug resistance, beta-lactam resistance, fluoroquinolone / fusidomycin, tetracyclines, macrolides, lincosamides, streptogramins or aminoglycoside resistance (see Figure 8A).

[0131] Preventing or treating antibiotic resistance may include the use of the particles on bacteria which do not yet show signs of antibiotic resistance, but which may do so in the future. Preventing or treating antibiotic resistance may include treating bacteria who already exhibit antibiotic resistance, for instance bacteria which have already been unsuccessfully treated with one or more types of antibiotic.

[0132] For instance, bacteria may have been previously treated using one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; tetracyclines (e.g. doxycycline and minocycline), aminoglycosides (e.g. gentamycin, tobramycin), MLS antibiotics (e.g. macrolides such as erythromycin, clarithromycin; lincosamides and streptogramins), floroquinolones (e.g. ciprofloxacin, levofloxacin), nitrofurantoin and trimethoprim. The bacteria may have been previously treated using one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; MLS antibiotics (e.g. macrolides such aserythromycin, clarithromycin; lincosamides and streptogramins), and aminoglycosides (e.g. gentamycin, tobramycin).

[0133] Thus, the antibiotic resistance may be resistance to treatment with one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; tetracyclines (e.g. doxycycline and minocycline), aminoglycosides (e.g. gentamycin, tobramycin), MLS antibiotics (e.g. macrolides such as erythromycin, clarithromycin; lincosamides and streptogramins), floroquinolones (e.g. ciprofloxacin, levofloxacin), nitrofurantoin and trimethoprim. The antibiotic resistance may be resistance to treatment with one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; MLS antibiotics (e.g. macrolides such as erythromycin, clarithromycin; lincosamides and streptogramins), and aminoglycosides (e.g. gentamycin, tobramycin).

[0134] Typically, the antibiotic resistance is associated with an infection or disease to be prevented or treated. The infection or disease may be one which does not exhibit antibiotic resistance, but which may do so in the future. In this instance, the porous carbon particles may be used to prevent antibiotic resistance developing, thereby permitting the treatment of the infection or disease with antibiotics.

[0135] The infection or disease may be one which has already been unsuccessfully treated with one or more types of antibiotic. For instance, the infection or disease may be one which has been previously treated using one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; tetracyclines (e.g. doxycycline and minocycline), aminoglycosides (e.g. gentamycin, tobramycin), MLS antibiotics (e.g. macrolides such as erythromycin, clarithromycin; lincosamides and streptogramins), floroquinolones (e.g. ciprofloxacin, levofloxacin), nitrofurantoin and trimethoprim. The infection or disease may be one which has been previously treated using one or more antibiotics selected from beta-lactams such as penicillins (e.g. amoxicillin, phenoxymethylpenicillin, flucioxacillin, co-amoxiclav), cephalosporins (e.g. cefalexin and cefaclor), monobactams and carbapenems; MLS antibiotics (e.g. macrolides such as erythromycin, clarithromycin; lincosamides and streptogramins), and aminoglycosides(e.g. gentamycin, tobramycin). Thus, the subject may be a subject who has an infection or disease which has previously been treated with one or more antibiotics as described herein. Typically, the subject is a subject who has an infection or disease which has previously been unsuccessfully treated with one or more antibiotics as described herein.

[0136] Typically, the biofilm-mediated disease or antibiotic resistance is associated with the presence of Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa, Enterob acteriaceae, coagulase-negative staphylococci, Streptococcus spp., Acinetobacter spp., Enterococcus spp pathogens, or a multidrugresistant (MDR) pathogen. For instance, the biofilm-mediated disease may be associated with a biofilm comprising one or more of Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa, Enterob acteriaceae, coagulasenegative staphylococci, Streptococcus spp., Acinetobacter spp., Enterococcus spp pathogens, or a multidrug-resistant (MDR) pathogen. Typically, the biofilm-mediated disease is associated with the presence of Enterob acteriaceae or Streptococcus spp.

[0137] The antibiotic resistance may be associated with an antibiotic resistant organism selected from Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa, Enterob acteriaceae, coagulase-negative staphylococci, Streptococcus spp., Acinetobacter spp., Enterococcus spp pathogens, or a multidrugresistant (MDR) pathogen. Typically, the antibiotic resistance is associated with Enterob acteriaceae or Streptococcus spp.

[0138] The porous carbon particles described herein may be administered in combination with one or more further therapeutic agents. The porous carbon particles and the one or more further therapeutic agents may be administered simultaneously, separately or sequentially.

[0139] Suitable further therapeutic agents may be selected from:

[0140] (i) an antibiotic, for instance any of the antibiotics as described herein;

[0141] (ii) an ammonia-lowering agent, such as lactulose, L-ornithine L-aspartate, L-omithine phenyl acetate or Rifaximin;

[0142] (iii) faecal microbial transplantation;

[0143] (iv) a corticosteroid; and / or

[0144] (v) drugs that target diseases selected from infections, chronic infections, periodontitis, cystic fibrosis, urinary tract infections, infective endocarditis, or a chronic wound.

[0145] The present invention also relates to a method of treating or preventing a biofilm-mediated disease, the method comprising administering porous carbon particlesas defined herein to a subject in need thereof. Preferably the disease is selected from an infection, a chronic infection, periodontitis, cystic fibrosis, a urinary tract infection, infective endocarditis, a chronic wound or a disease resulting from ingestion of a substance or particle comprising a biofilm.

[0146] The present invention also relates to a method of treating or preventing antibiotic resistance, the method comprising administering porous carbon particles as defined herein to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

[0147] The porous carbon particles of the present invention may be administered in a variety of dosage forms. Thus, the porous carbon particles may be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The porous carbon particles may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The porous carbon particles may also be administered rectally, for example in the form of a suppository. A physician will be able to determine the required route of administration for each particular patient.

[0148] Preferably, the porous carbon particles are administered orally or rectally. When administered orally or rectally, the porous carbon particles act intraluminally in the gut, since they are non-absorbable. Preferably, the porous carbon particles are administered orally, for example in free-flowing form (suitably provided in a sachet) or tablet form.

[0149] In another embodiment, the porous carbon particles may be used in a method of treating blood extracorporeally, by passing blood through a medical device containing the carbon particles before it is returned to the body, wherein the blood is from an individual having a biofilm-mediated disease, or from an individual suffering from an infection or disease which exhibits antibiotic resistance. This method may be achieved by any suitable means. Blood which has been treated in this way may be returned to the individual for therapeutic purposes, or may be used for another purpose. For example, blood may be treated in this way prior to transfusion into a different individual.

[0150] The formulation of the porous carbon particles will depend upon factors such as the nature of the exact agent, whether a pharmaceutical or veterinary use is intended, etc. An agent which is to be used to treat disease may be formulated for simultaneous, separate or sequential use.

[0151] The porous carbon particles are typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. Thepharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, com starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or filmcoating processes.

[0152] Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and / or mannitol and / or sorbitol.

[0153] Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

[0154] Formulations for oral administration may be formulated as controlled release formulations, for example they may be formulated for controlled release in the large bowel.

[0155] Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

[0156] The dose of the porous carbon particles may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen.

[0157] Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 2 g per kg of body weight, according to the age, weight and conditions of the individual to be treated, the type and severity of the degeneration and the frequency and route ofadministration. Daily dosage levels may be, for example, from 0.5 to 15 g, preferably from 1 to 15 g, more preferably from 4 to 12 g or 8 to 15 g, more preferably from 8 to 12 g, more preferably from 10 to 12 g, or if appropriate higher daily dosages such as 10 to 100 g, preferably 20 to 80 g, may be used. Preferably, the daily dosage is administered all in one unit dose.

[0158] A physician will be able to determine the required time schedule of administration for any particular patient. Best practice dictates that a dose of the porous carbon particles should be administered to a patient (i) at least 4 hours after the patient has consumed a meal to ensure that the consumed food has cleared the stomach, and / or (ii) at least 6 hours before the patient is administered with any further therapeutic agent.

[0159] All publications and patent applications mentioned in this specification are indicative of the level of those skilled in the art to which this invention pertains.

[0160] All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually to be incorporated by reference.

[0161] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of understanding, it will be clear to those skilled in the art that certain changes and modifications may be practiced within the scope of the appended claims.

[0162] Certain aspects of the invention

[0163] Certain aspects of the invention are disclosed below.

[0164] 1. Porous carbon particles for use in a method of preventing or treating a biofilm- mediated disease, wherein: said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm; and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said biofilm-mediated disease.

[0165] 2. Porous carbon particles for use in a method of preventing or treating antibiotic resistance, wherein: said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, andsubstantially no large macropores of diameter greater than 500 nm; and said method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

[0166] 3. Porous carbon particles for use according to aspect 1 or 2, wherein mesopores of diameter greater than 2 nm and less than 30nm and large macropores of diameter greater than 500 nm together make up 10% or less of the total pore volume of the porous carbon particles.

[0167] . Porous carbon particles for use according to any one of the preceding aspects, wherein 5 to 30% of the total pore volume of the porous carbon particles is made up of pores having a mean diameter of from 0.6 to 2 nm.

[0168] 5. Porous carbon particles for use according to any one of the preceding aspects, wherein 85% or more of the pore volume of the porous carbon particles which is made up of pores having a mean diameter greater than 2nm is made up of pores having a mean diameter of from 30 nm to 500 nm, preferably wherein 90% or more of the pore volume of the porous carbon particles which is made up of pores having a mean diameter greater than 2nm is made up of pores having a mean diameter of from 30 nm to 500 nm, preferably from 50 nm to 300 nm, preferably from 50 nm to 200 nm.

[0169] . Porous carbon particles for use according to any one of the preceding aspects, wherein the total pore volume is from 0.5 to 2.5 cm3g'1.

[0170] 7. Porous carbon particles for use any one of the preceding aspects, wherein the volume of pores having a mean diameter of from 0.5 to 2 nm in the porous carbon particles is 0.1 to 1.1 cm3g-1and the volume of pores having a mean diameter of from 30 to 500 nm is 0.8 to 2.5 cm3g-1.

[0171] 8. Porous carbon particles for use according to any one of the preceding aspects, wherein the total specific surface area as measured by a BET (Brunauer-Emmett- Teller) method is greater than 700 m2 / g.

[0172] 9. Porous carbon particles for use according to aspect 8, wherein the total specific surface area is greater than 1000 m2 / g.

[0173] 10. Porous carbon particles for use according to aspect 9, wherein the total specific surface area is from 1400 to 2000 m2 / g.

[0174] 11. Porous carbon particles for use according to any one of the preceding aspects, wherein the particles are in the form of spherical particles.12. Porous carbon particles for use according to any one of the preceding aspects, wherein the particles are administered orally or rectally.

[0175] 13. Porous carbon particles for use according to aspect 12, wherein the particles are administered orally in free-flowing form or in tablet form.

[0176] 14. Porous carbon particles for use according to any one of the preceding aspects, wherein the porous carbon particles are coated in order to control their release and adsorption properties.

[0177] 15. Porous carbon particles for use according to aspect 14, wherein the porous carbon particles are coated with a film that will allow predominant release into the large bowel.

[0178] 16. Porous carbon particles for use according to any one of aspects 1, or 3 to 15, wherein the biofilm-mediated disease is an infection, a chronic infection, periodontitis, cystic fibrosis, urinary tract infection, infective endocarditis, a chronic wound or disease resulting from ingestion of a substance or particle comprising a biofilm.

[0179] 17. Porous carbon particles for use according to any one of aspects 2 to 15, wherein the antibiotic resistance is associated with an infection or disease to be prevented or treated.

[0180] 18. Porous carbon particles for use according to any one of aspects 1 to 17, wherein the biofilm-mediated disease or antibiotic resistance is associated with the presence of Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa, Enterob acteriaceae, coagulase-negative staphylococci, Streptococcus spp., Acinetobacter spp., Enterococcus spp pathogens, or a multidrug-resistant (MDR) pathogen.

[0181] 19. Porous carbon particles for use according to any preceding aspect, wherein the porous carbon particles reduce the expression of virulence factors.

[0182] 20. A method of treating or preventing a biofilm-mediated disease, the method comprising administering porous carbon particles as defined in any one of aspects 1 to 14 to a subject in need thereof, thereby preventing or treating said biofilm- mediated disease.

[0183] 21. Use of porous carbon particles as defined in any one of aspects 1 to 15 in the manufacture of a medicament for treating or preventing a biofilm-mediated disease.22. A method of treating or preventing antibiotic resistance, the method comprising administering porous carbon particles as defined in any one of aspects 1 to 15 to a subject in need thereof, thereby preventing or treating said antibiotic resistance. 23. Use of porous carbon particles as defined in any one of aspects 1 to 15 in the manufacture of a medicament for treating or preventing antibiotic resistance.

[0184] Examples

[0185] The following Examples illustrate the invention:

[0186] Materials and Methods

[0187] Carbon materials

[0188] Preparative Example 1

[0189] A solution of 100 parts by weight of industrial Novolac resin with an average molecular weight 700-800D (Hexion Specialty Chemicals) in ethylene glycol was heated to 90-95°C and thoroughly mixed for 2-5 minutes with a solution of 15 - 20 parts by weight of hexamethylenetetramine (hexamine) in ethylene glycol heated to the same temperature. The resulting clear solution was poured in a stream into 2.5-6 fold volume of stirred hot (150-155°C) low viscosity mineral oil (insulating oil or transformer oil) containing 0.2 - 1% (v / v) of a dispersing agent which was an industrial drying oil (Danish oil), a major component being polyunsaturated (oxidised) vegetable oils. The temperature of the mixture fell to 135-140°C, and the mixture was reheated to 150-155°C over a period of 15-20 minutes. Typically curing occurred within 1-2 minutes at around 140°C followed by substantial evolution of gas. The further heating to 150-155°C for 15-20 minutes ensured the completion of curing. The mixture was cooled and the resulting beads were separated from the oil by filtration or centrifugation Ethylene glycol was removed from the resin either by multiple hot water extraction or by drying in vacuum (120°C at 50 mm Hg). In the above procedure, compared to Example 3 of WO 02 / 12380, the hexamine content has been increased to 15-20pbw per lOOpbw of novolac from the previously exemplified 9 pbw, and the temperature of the oil into which the resin solution is poured is increased from 115-120°C to 150-155°C, and “flash” cure is brought about rather than a “slow” cure as previously exemplified.Water- washed wet, dried or vacuum-dried resin beads were heat treated to produce carbon materials. A typical procedure comprised but is not restricted to carbonisation in a flow of carbon dioxide with temperature ramping from ambient to 800°C at 3°C / min, classification by particle size and further “physical” activation of selected fraction in carbon dioxide flow at 900°C. Many variations of this routine known in the art may also be applied. The degree of activation in these samples was approximately 30%.

[0190] The meso / macro pore size distribution in the resulting carbons is pre-determined by the porosity of the resin-precursor, which is controlled by the content of the solvent / pore former and the degree of activation of the resulting carbon. Table 1 below gives details of four resin compositions that are precursors to the meso / macro porous carbons, as illustrated by nitrogen porosimetry and mercury porosimetry tests of the activated materials. The predominantly micro - macroporous materials, TE7 and TE8 have a very similar macropore structure. The TE3 and TE5 materials, which have smaller pores in the meso / macro domain are for illustration and give inferior performance in the adsorption of the larger molecules such as TNFa.

[0191] The particle size distribution of resulting resin beads depends on various parameters including but not restricted to the type of stirring tool, stirring rate, viscosity of the resin solution, concentration of the dispersing agent, resin solution to oil ratio and temperature of the dispersion. Though the distribution is typically broad the size of the predominant fraction could effectively be shifted between ~10 micron and ~1 mm.

[0192] Table 1

[0193] Product Novolac solution Hexamine solution

[0194] Code

[0195] Novolac Ethylene Hexamine Ethylene

[0196] Glycol Glycol

[0197] TE3 100 pbw 80pbw 20 pbw lOOpbw

[0198] TE5 100 pbw lOOpbw 20 pbw 120pbw

[0199] TE7 100 pbw 150pbw 20 pbw 150 pbw

[0200] TE8 100 pbw 150pbw 20 pbw 180pbw

[0201]

[0202] Preparative Example 2: Activation of the Carbonised Beads

[0203] The resin beads may be activated in either carbon dioxide or steam. Carbon dioxide is more controllable whilst steam is preferred for larger scale preparations on acost basis. Activation in carbon dioxide occurs at around 900C with the degree of bum off controlled by the residence time in the furnace. Steam activation preferably takes place at around 700C. In both cases the conditions are not critical and the temperature and time can be adjusted to give the required degree of activation as known by anyone skilled in the art. The effect of carbon dioxide activation on the pore structure of the TE8 beads is shown in Figure 3 with the pore distribution summarised in table 2. The increase in the micro pore volume can be seen from Figure 3. It can also be seen from table 2 that the pore volume in the micropores (<2nm) is very low (0.1cm3 / g) in the unactivated sample which also corresponds to the low BET surface area (534m2 / g).

[0204] Activation to at least 30% bum off significantly increases both the micropore volume and the surface area. The preferred materials for the biomedical adsorption have areas of at least 1000m2 / g, micropore volumes in excess of 0.3cm3 / g.

[0205] Table 2 Pore structures for CO2 Activated TE8 Carbons

[0206] Tc-ts; 70’ .0.99! ^tre^e-ra -ere Vo'ure Valeria Ce-Al SET Area 099 2- 5!?"^ >5P’’rr ,S',1CT3 . . c / TlS . r’U c-"3- c TES •.J- activate ci 53A 0.9 0 101 v 136 056 291 act'vatec 0.22 ICu; 131 0 34 0 22 0.66

[0207]

[0208] 47L 3U- cU 0 1? 1432 1 o? 0.355 061 The change in the macropore volume of the carbon with activation is an artefact of the nitrogen adsorption method but should be >0.5cm3 / g. The larger pore structures should be measured using mercury porosimetry. These are shown for TE7 and TE8 activated to 40% bum off in Figure 2. The larger pores at >38000nm are due to interparticle voids between the beads, not to any internal porosity within the beads. The TE7 and TE8 particles have pore diameter peaks at 88 nm and 91 nm respectively, surface area of 1499 m2 / g, pore volume of 1.36 cm3 / g, bulk density of 0.2 g / cm3, particle size of 240-500 pm and 40% degree of activation. The absence of pores both above the main peak (>300nm) is readily apparent as is the essential absence of the pores in the mesopore (2-50nm) domain for both materials. Mercury cannot provide data in pores below ~6nm due to the pressure involved.

[0209] Materials for studies

[0210] Activated carbon samples according to the invention were acquired from MAST Carbon International Ltd, UK. The activated carbon samples are referred to as Yaq-001.Scanning Electron Microscopy analysis

[0211] Yaq-001 samples were mounted on aluminium stubs using carbon adhesive tape and coated with a 2nm thick layer of platinum using a Quorum Q150TES coater (Quorum Technologies, UK). The surface as well as internal morphology was examined using a Zeiss Sigma field emission field emission scanning electron microscope (FESEM) (Carl Zeiss Microscopy, Germany) at an accelerating voltage of 5 kV at 100, 500 and 50000x magnifications.

[0212] Pore size distribution by Mercury Porosimetry

[0213] Mercury porosimetry analysis was performed using a mercury porosimeter PoreMaster (Quantachome Instruments, USA). Prior to the analysis, all materials were dried in a vacuum oven at 110 °C under 800 bar vacuum for 3 hours. The meso- (2-50nm) and macro- (diameter >50 nm) pore size distributions of the Yaq-001 samples were determined by mechanical intrusion of mercury. Data was analysed using PoreWin 6.0 software (Quantachrome Instruments, USA).

[0214] Example 3 - Impact of YaqOOl on the gut microbiome in patients with cirrhosis Introduction

[0215] Cirrhosis pathogenesis has been closely linked to the microbiome, particularly in advanced disease stages (1-3). Bacterial products like endotoxin translocate from the gut to the liver and systemic circulation, driving dysregulated inflammatory responses and subsequent organ injury (4, 5). Current interventional strategies to modulate this process are limited to the use of oral antibiotics, which aim to reduce bacterial overgrowth and endotoxemia in cirrhosis (6-8). Sometimes those treatments necessitate their chronic administration for secondary prophylaxis of hepatic decompensation (9, 10). While antibiotics may provide short-term benefits, they do not address the underlying gut microbiome dysbiosis and can exacerbate long-term complications, such as the development and accumulation of antimicrobial resistance (AMR) of virulent strains (11). AMR has been recognized as one of the greatest challenges facing modern medicine (34). Antibiotic administration is particularly common among liver disease patients due to their compromised immune systems. Therefore, there is a critical need for safer, alternative therapeutic strategies that could be used for both primary andsecondary prophylaxis, offering a more effective and sustainable approach to managing cirrhosis.

[0216] YaqOOl is a novel, non-absorbable nanoporous carbon bead adsorbent designed to target gut-related pathophysiological processes (12, 13). Preclinical studies in cirrhosis models demonstrated its ability to reduce fibrosis, portal hypertension, and organ dysfunction, likely through the restoration of a dysbiotic gut microbiome and reduction in endotoxemia (14). A Phase 2, randomized, placebo-controlled trial (CARBALIVE-SAFETY STUDY) assessed the safety and efficacy of oral YaqOOl in patients with decompensated cirrhosis (15, 16). In this trial, 28 patients with cirrhosis were randomly assigned (double-blind) to receive either YaqOOl (4g once daily) or placebo. Samples, including blood, urine, and stool, were collected at baseline, 4 weeks, and 12 weeks. The primary endpoints focused on safety and tolerability, while secondary endpoints included blood endotoxin levels, organ function, and nutritional status. No serious adverse events or significant differences in adverse events between groups were observed. Gastrointestinal-related adverse events were noted but were comparable between groups (14). Exploratory endpoints investigated microbiome composition and functionality, as well as local and systemic inflammatory indices and markers of intestinal barrier permeability.

[0217] This sub study, conducted as part of the CARBALIVE-SAFETY trial, aims to comprehensively explore the effects of YaqOOl on the gut microbiome, including its composition and functional aspects such as virulence factors (VF) and antibiotic resistance genes (ARGs). Whether these microbiome changes are associated with changes in markers of gut inflammation, metabolism, and gut permeability was also investigated, as well as their potential impact on systemic inflammation and bile acid metabolism to better understand the systemic implications of these changes in the context of cirrhosis.

[0218] METHODS

[0219] Study Design and Patients

[0220] A group of 28 patients with liver cirrhosis were randomly assigned into Active and Placebo groups as described (Figure 9) (14).

[0221] Serum and stool samples were collected at three different timepoints: baseline, week 4, week 12. In Serum samples biomarkers associated with gut permeability, systemic inflammation, nutrition, intestine integrity, kidney function, and endothelialfunction were measured. Targeted metabolomic in serum samples were also performed. For fecal samples biomarkers associated with gut inflammation, gut integrity, and metabolism were measured (Figure 5 A). All the subjects who took at least 70% of the treatment doses (2 sachets / day for Cohort 1) and did not present major protocol non-compliances were included in this analysis. All measures of efficacy including laboratory tests are also performed on this population.

[0222] Core laboratory analyses

[0223] Luminex Assay

[0224] The Luminex Assay Protocol was performed in accordance with the manufacturer’s instructions. In brief, 50mcl of sample / standard and 50mcl of Microparticle Cocktail are added to a 96 well plate, sealed and incubated for 2 hours at room temperature on a horizontal orbital microplate shaker. The plate was then washed three times with wash buffer and 50pL of diluted Biotin Antibody Cocktail added to all wells. The plate was sealed and incubated for 1 hour at room temperature. 50pL of Streptavidin-PE was then added to all wells and incubated for 30 minutes at room temperature. Following washing with buffer, the microparticles were then resuspended in Wash Buffer and incubated for 2 minutes at room temperature. The plate was then read within 90 minutes using Bio-Plex® MAGPIX™ Multiplex Reader and analysed on xPONENT software.

[0225] Faecal cytokine analysis and D-lactate assays

[0226] Faecal cytokine analysis and D-lactate assays were performed as described in reference 17.

[0227] Bile Acids (BAs) Analysis

[0228] Cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid, ursodeoxycholic acid and their glycine and taurine conjugated species were identified and quantified by ultra-performance liquid chromatography - quadrupole time-of-flight mass spectrometry (UPLC / Q-TOF-MS). Mass spectrometry analysis was performed using Xevo G2-XS Qtof system from Waters using an electrospray interface. BAs were separated by elution gradient mode with a mobile phase composed of a mixture of ammonium acetate buffer 15 mM, pH 8.0 (Solvent A) and acetonitrile: methanol = 75:25 v / v (Solvent B). The separation was obtained with a total run time of 6 minutes.All the chromatograms were acquired in electrospray negative ionization with the mass spectrometer operating in multiple reactions monitoring mode.

[0229] Analysis of Short-chain fatty acids (SCFAs) in stool

[0230] Prior to analysis, Eppendorf tubes were weighed and approximately lOOmg of stool was added to individual tubes. These stool samples were then homogenized in ImL of buffer (0.1M Tris, 0.15MNaCl, IM urea, lOmM CaC12, 0.1M citric acid monohydrate, 5g / L bovine serum albumin (BSA) and 0.25mM thimerosal, pH 8.0) using a plastic homogenizer.

[0231] Sample preparation and derivatization: 20mL of stool sample and 15mL of Internal standard mix was added to a fresh glass vial. The volume in the vial was adjusted to lOOmL with d.H2O. 500mL of 0.1M TBA (tetrabutylammonium bisulfate in 0.1M KH2PO4 (pH 7.4) was added to each vial followed by 500mL of 2% PFBBR (Pentafluorobenzyl bromide) in dichloromethane. Samples were then sonicated for 60 minutes. Samples were extracted into 2mL of hexane and centrifuged at 1500rpm for 5 minutes at 4°C. The organic phase was moved to a fresh glass vial and evaporated under N2 gas to approximately lOOmL. lOOmL of sample was then transferred to a glass autosampler vial and run via GCMS. Samples were analysed on Rxi®-5Sil MS fused silica, 30m x 0.25mm I.D, 0.25pm film thickness), Inlet Temperature: 280°C, MS Transfer line: 250°C, Split ratio: 1: 10, carrier gas (Helium) flow rate: 0.9ml / min, ion source: 225°C, chemical ionization (Methane 2mL / min). Oven temperature was programmed from 45°C to 200°C at 10°C / min, then to 300°C at 30°C / min. Negative ions were detected in selected ion monitoring: The remaining stool sample was dried overnight using a vacuum centrifuge and dry weight was calculated.

[0232] NMR analysis

[0233] Aliquots of plasma (from blood collected into lithium heparin tubes) and urine were stored frozen at -80oC until NMR analysis. All samples were gently thawed in preparation for NMR analysis at the Biomolecular NMR Centre, King’s College London.Urine and serum samples were prepared for NMR analyses using standardised protocols. NMR data were acquired at the Centre for Biomolecular Spectroscopy, King’s College London using a Bruker 600MHz (AVANCE NEO) NMR spectrometer and a 1H / 13C / 15N TCI Prodigy (nitrogen-cooled) probe. Pulse-collect (urine, serum) and spin-echo (serum) ID NMR data sets were acquired using PURGE watersuppression and the PROJECT spin-echo sequences. Paired NMR data were compared using principal component analyses (PCA) (Wiley Sciences Solution KnowItAll® Informatics, Metabolomics Edition v!7.0, and MetaboAnalyst 4.0).

[0234] Analysis of alterations on the microbiome

[0235] DNA extraction

[0236] Performed using routine laboratory procedures.

[0237] Metagenomic sequencing.

[0238] Stool samples were sequenced using Illumina HiSeq 2000, were analysed. All metagenomes passed over half the quality metrics in FastQC 0.11.3 with pass rates calculated in MultiQC.

[0239] Gene and Species abundance profding

[0240] The raw reads for all samples were trimmed using Alien Trimmer 0.4.0 with parameters -k 10 -145 -m 5 -p 40 -q 20 and Illumina contaminant oligonucleotides (18). Trimmed samples were mapped against the IGC2 using Bowtie integrated into the METEOR pipeline (https: / / forgemia.inra.fr / metagenopolis / meteor) against a catalogue that contains Metagenomic Species Pan-genomes (MSPs) of the human gastrointestinal microbiota built by binning co-abundant genes of the IGC2 (19, 20) catalogue with MSP miner (21, 22). Human contaminant sequences were removed from all samples by discarding reads that mapped against a human reference genome. Downsizing of the gene count tables was done using the MOMR downsize and a cutoff of 10M reads. Matrix function was used to eliminate the sequencing depth fluctuations. Normalization of the downsized gene count tables was performed using the MOMR norm FreqRPKM function and according to the FPKM strategy. MSP abundances were estimated using mean abundance of 100 ‘marker’ genes (highly correlated within the MSP). Less than 10% of ‘marker’ genes were assumed to have species abundance of 0.

[0241] Functional annotation of Genes in IGC2 catalogue

[0242] Protein sequences of the IGC2 catalogue were annotated for Antibiotic Resistance Genes using the DeepARG software (23), using a minimum probability cutoff of 0.9. Proteins of IGC2 catalogue were annotated to KEGG orthologs usingDiamond against KEGG database. Best-hit alignments with e-value < 10\A-5.

[0243] Annotation of Virulence Factors was performed running blastp with an e-value cutoff of lel0-10 and a minimum percentage identity of 65% against the set of sequences provided in the VFDB Database of Virulence Factors (24). Annotation of Secondary Bile Acid genes was performed running blastp against Sequences of Genes and suggested cutoffs reported in (25).

[0244] Statistics

[0245] Differential abundance analysis of MSP abundance, and genes abundance between Placebo and Active arms was performed using Mann-Whitney U- tests, two tailed, with a cutoff p-value of 0.05. For comparing the Effect on biomarkers between Active arm and Placebo, first for each subject we measured the Log-2 Fold Change after 4 and 12 weeks in relation to baseline. Then the Change between Active and Placebo samples at the same week was compared using a Mann-Whitney U-test, altemative=less. Correlations between MSP abundance and measured biomarkers was performed using Spearman correlation test.

[0246] RESULTS

[0247] In this study, the effect of YaqOOl administration was compared to that of placebo, on the microbiome composition as well as local and systemic inflammatory indices and markers of intestinal barrier permeability in liver cirrhosis patients (Figure 5 A). No significant differences in clinical and biochemical variables, prognostic scores such as the Child-Pugh score or the MELD scores were observed between groups. The rate of adverse events between the two groups were similar. As shown in the previous publication, the nutritional state and associated markers were similar between groups (14).

[0248] YaqOOl leads to an improvement in biomarkers associated with systemic imflammation, gut permeability and endothelial function

[0249] Systemic Inflammation and endothelial function

[0250] Of the large number of markers of systemic inflammation measured, significant improvements in the following serum biomarkers in the Active arm in comparison to the control Placebo group were observed. Angiotensin-converting enzyme (ACE), C-reactive protein (CRP), CXCL10 and asymmetric dimethyl arginine (ADMA) (Figure 5B and Figure 10 A) showed a decrease after 12 weeks in the YaqOOl and no improvement in the Placebo group. ACE is involved in the conversion of angiotensin I into the vasoconstrictor angiotensin II, promoting fibrosis and increased portal pressure within the liver (26). CRP functions as part of the innate immune system by binding to damaged cells and pathogens, rapidly increasing in concentration in the bloodstream when tissue injury or infection occurs. Persistently high CRP levels in cirrhotic patients have been associated with complications such as decompensation, bacterial infections, and mortality. CXCL10 acts as a pro-inflammatory chemokine, attracting immune cells to the site of injury contributing to hepatic inflammation and fibrosis. Increase in asymmetric dimethyl arginine (ADMA) has been associated with impaired liver function. ADMA inhibits endothelial nitric oxide synthase (NOS) activity resulting in endothelial dysfunction and abnormalities of the hepatic microcirculation and portal hypertension (27, 28). An increase was observed in the Placebo group, and a stable behavior in the Active group. Additionally, a reduction in cytokeratin M30 index in the Placebo Group was observed but the numbers were within the normal range (Figure 10F)

[0251] Gut permeability

[0252] Improvement in the Lactulose / L-Rhamnose ratio, which is a marker of gut permeability, was found (Figure 5B). The intestinal mucosal surface acts as the first barrier of defense against pathogens and antigen triggers. Under healthy conditions very little Lactulose is absorbed from the gut, however, following damage in this barrier, lactulose may be absorbed into the blood in greater amounts. The data suggest an increase of this marker compared with the Placebo group, and a stable behavior in the Active arm group.

[0253] Gut Metabolism and endothelial function

[0254] A reduction in the acetic acid, propionic acid, and butyric acid concentrations in the Active arm group (Figure 10D) and no differences in the Nutrition Biomarkers (Figure 10E). However, the mean value of the concentration at the end of the treatment in the Active arm are 63.5, 7.3, and 14.5 pmole / g wet weight for acetic acid, propionic acid and butyric acid, respectively, which fall within the normal healthy ranges.Markers of gut inflammation

[0255] Although there were trends towards lower pro-inflammatory cytokines and increased anti-inflammatory cytokines in the faeces of the patients in the Active arm, the differences were not statistically different in any of the biomarkers measured in fecal samples (Figure 11).

[0256] YaqOOl modulates the microbiome promoting benefic species and reducing the abundance of some pathogen associated species

[0257] To evaluate the changes in the composition of the gut microbiome to the treatment and placebo, shotgun metagenomics were performed on 70 samples, with minimum of 15 million reads. The raw sequences were filtered and mapped against gut non-redundant gene catalogue consists of 10 million genes (19, 20). After the normalization based on the determined gene counts for each sample, the metagenome species (MGS) abundances were calculated using the gene counts. After YaqOOl treatment, the species richness between the Placebo and Active groups was found across any of the three visits (Figure 6A). Additionally, when comparing the distribution of the Bray Curtis distance within individuals at different timepoints between Placebo and Active groups, no significant differences were observed (Figure 6B). This could indicate that the minimal changes in the overall microbial community composition through time, are similar in both Active and Placebo groups.

[0258] Comparing the effect of YaqOOl with Placebo at the level of individual microbes, most bacteria that increased in abundance in the YaqOOl group have been associated with promoting gut health, such as Adlercreutzia equolifaciens, a commensal bacterium with anti-inflammatory properties commonly depleted in liver disease (29). Also, increased level of faecalibacterium prausnitzii were observed, a commensal bacteria and significant butyrate producer with anti-inflammatory properties, which increased in active arm at week 12. In contrast, most of the species showing decreased abundance after treatment have been associated with infections and poor outcomes in liver disease patients, such as Klebsiella pneumonia (30, 31) and Streptococcus mutans (32) (Figure 6C).

[0259] To reveal the functional landscape of the changes in the gut microbiome, differential abundance analysis of genes grouped by KEGG orthologue (KO) annotations between Active and Placebo arms was performed. The functional categories with most genes changing in abundance were the ABC transporters, two componentsystems and biofilm formation, both related with external bacterial components. The metabolic pathways of arginine biosynthesis, cysteine and methionine, galactose, methane, oxidative phosphorylation, and biosynthesis of nonribosomal peptide siderophores had at least three depleted enzymes in the active arm group (Figure 6D). Notably, within the biofilm formation category, only genes decreasing in abundance were observed in the Active arm. Biofilm formation plays a crucial role in pathogenesis, allowing bacteria to adhere to surfaces, providing protection against the immune system and antibiotics, leading to difficult to treat infections. These observations suggest the effect of YaqOOl treatment impacts the membrane or extracellular components of the affected species.

[0260] YaqOOl treatment decreases genes in the microbiome associated virulence and antimicrobial resistance

[0261] As observed above, bacterial species decreasing in abundance in the Active arm have been described as pathogenic. Consequently, differential abundance analysis of the microbiome genes coding for virulence factors was performed comparing Active vs Placebo groups (Methods). Virulence factors (VFs) are bacterial components providing pathogenic bacteria an increased capacity to infect the organism (33). All differentially abundant VF genes showed a decrease in abundance in the Active arm compared with the Placebo group, with a greatest decrease in week 12 (Figure 7A-B).

[0262] The overall cluster of VF genes were linked to adhesion, nutritional factors, effector delivery systems, immune modulation, regulation, invasion, and antimicrobial resistance categories (Figure 7A). The two most frequent categories were adhesion and nutritional factors. Adhesion VF enable bacterial attachment, invasion, and biofilm formation; for example, fibronectin binding protein (FBP) promotes fibronectin-mediated collagen recruitment, which leads to matrix deposition on and between streptococcal cells to induce the formation of large bacterial aggregates. In the nutritional VF category, genes related to metal ion uptake, like psaA, were mostly found. The key function psaA is the transport of Mn2+ and Zn2+ into the cytoplasm of the bacteria; psaA mutants show marked impact on the capacity to colonize and increased susceptibility to oxidative damage. Also, within this category, we observed the Sal gene, a major trigger of inflammation and bacterial dissemination during K. pneumonia lung infection. Those genes linked to adhesion and nutritional factor categories showed the greatest reduction in the relative abundance at the end of thetreatment (Figure 7C). A broad range of bacterial families were associated to the changing VFs where the Streptococcaceae family showed the greatest changes after treatment (Figure 7C).

[0263] Interestingly, significant negative correlations between the gene abundance of VFs, like FBP and psaA, within the Streptocaccaceae family and the ACE biomarker were observed, one of the improving biomarkers after Carbalive treatment (Figure 7D).

[0264] Identifying VFs as one of the key phenotypic changes and also as the YaqOOl treatment reduced some of the opportunistic pathogens, it was hypothesized that the treatment could result potentially in the reduction of antimicrobial resistant (AMR) genes in gut microbiome. Antimicrobial resistance genes (ARGs) pose a significant concern when carried by pathogenic bacterial strains. Moreover, the ARG and VF genes are intertwined and can overlap. Therefore, the genes for the AMR were annotated using Deep ARG software (23). Then the impact of treatment was investigated, by performing a differential abundance analysis of predicted ARGs between the Active and Placebo groups. Most of the differentially abundant AMR genes showed a decrease in abundance in the Active group (Figure 8 A, 8B). As observed with VFs, AMR genes linked to the Streptococcaceae family showed the greatest reduction in the Active group. Among the AMR families, multidrug resistance (MDR), with RamA and oqxB showed the highest log fold change, both of which have efflux pump mechanism, and both are also linked to the Enterobacter and / or Streptococcus species (Figure 8A, 8B). Beta-lactam resistance was another family of genes with dramatic decrease after treatment with significant genes PBPla and PBPlb linked to the Streptococcus pneumoniae. These ARGs reduced the affinity of the bacteria for binding antibiotics, especially the beta-lactams. Aminoglycosides contain large array of resistant genes against gram negative bacteria was another specific domain of AMR with significant decrease of CfxA3, a class A beta-lactamase.

[0265] As observed with virulence factors, ARGs linked to the Streptococcaceae and Enterobacter family showed the greatest reduction in the Active group.

[0266] Effect YaqOOl on fecal and serum bile acids (BAs) and microbiome genes linked to its metabolism

[0267] The intestinal microbiota can influence the size and composition of the bile acid pool in serum and alterations in the secondary bile acid pool have been observed in liver cirrhosis patients (35). Therefore, testing for differential abundance of genes reported toparticipate in the secondary bile acid metabolism was conducted and compared these to changes in faecal and serum secondary bile acid concentration in relation to baseline in Active and Placebo groups. After YaqOOl treatment, only the BaiCD gene changed showed a decrease in abundance in the Active group (Figure 12). In serum, TLCA and GLCA showed a trend towards increasing in the active arm but not in placebo at week 12. In fecal samples, GCA, TCDCA, GCDCA, and LCA showed trends to an increase in the Active arm compared to Placebo at week 12 (Supplementary Figure 12).

[0268] DISCUSSION

[0269] YaqOOl is a novel, orally administered therapeutic approach to sequester microporous and microporous substances and metabolites in the gut lumen without exerting antimicrobial activity (14). In animal models of cirrhosis, it has been shown to prevent progression of fibrosis, reduction in bacterial translocation, improvement of organ function, occurrence of acute on chronic liver failure with widespread effects on severity of endotoxemia, gene expression in multiple organs and positive effects on the microbiome. The CARBALIVE-SAFETY clinical trial was a randomized double-blind trial of YaqOOl in patients with cirrhosis, in which its safety and tolerability was confirmed. In this study, the blood, stool and urine samples obtained in the clinical trial were used to explore the biological effect of YaqOOl in these patients. The most important biological effect of YaqOOl was observed in the metagenome composition. A decrease of pathogenic bacterial species and an increase of autochthonous bacteria was observed, without major changes in the global microbiome composition. This was associated with functional changes in the microbial genes involved in membrane associated proteins linked to the virulence capabilites and antibiotic resistance. This was associated with favurable effects on biomarkers representing the intestinal barrier permeability, inflammation and endothelial function.

[0270] The metagenomic composition studies showed no significant difference in bacterial diversity, as evidenced by the Shannon index, with either YaqOOl treatment or Placebo groups. This is an important observation as it provides further evidence that YaqOOl does not exert an antibiotic effect and distinguishes it mechanistically from other microbiome targeting treatments such as antibiotics. In a previous in vitro study, no effect of YaqOOl on growth characteristics of the bacteria were observed in contrast to antibiotics, which prevented bacterial proliferation (14). Shifts in Klebsiella, Streptococcus in humans compared to favorably with shifts in Veillonella andRoseburia species in the mouse gut, indicative of a less hostile environment. These data are of particular importance as cirrhosis patients are prone to developing complications such as variceal bleeding, hepatic encephalopathy, ascites, bacterial infections and mortality, which have been associated with gut microbial changes. In cirrhosis patients with progressive disease, pathogenic bacteria such as Klebsiella and Streptococcus species become more abundant and can cause infections and progression of liver disease (1, 36, 37).

[0271] As has been shown previously, the presence of multiple microbial virulence factors, which are known to impact negatively on the outcome of cirrhosis patients (38) was observed. Although these factors are more widely observed in patients with more severely decompensated disease, it was interesting to note their presence in this population with well compensated cirrhosis. An important observation of this study was the significant impact of YaqOOl on the virulence genes, which encode for multiple virulence factors that extend to mechanisms that allow invasion of the host through secretion of fimbriae, generation of biofilm, secretion of siderophores, attachment processes and secreted lysins. YaqOOl may provide this effect by providing a physical barrier selectively decreasing the abundance of virulent species without exerting a selective pressure as is the case with antibiotic administration, which in the long run increases the risk of infection of resistant strains.

[0272] AMR is a particular issue in patients with cirrhosis who have greater susceptibility to development of infections due to cirrhosis-associated immune dysfunction. There are several mechanisms that contribute to this immune dysfunction but alterations in the microbiome composition, gut permeability, translocation and inflammation all seem to be important. AMR genes (ARGs) confer microbial communities with the ability to resist antibiotics and represent quorum-sensing and secretion systems that allow microbiota to survive through adaptations in genotypic responses to antimicrobials. The gut microbiome acquires ARGs leading to colonization with pathogenic organisms (39-43). The data in this study showed a marked reduction in the abundance of ARGs in the group treated YaqOOl compared with placebo with significant effects on ARGs associated with several antibiotics including beta lactams, aminoglycosides, MLS and multidrug resistance genes. The reduction in the abundance of the Streptococcus and Klebsiella species contribute to the reduce burden of ARGs.

[0273] The biomarkers related with systemic inflammation showing improvement included ACE, CRP, and CXCL10. Systemic inflammation is central to thepathogenesis of complications of cirrhosis, most markedly acute decompensation and acute on chronic liver failure. ACE is involved in the conversion of angiotensin I into the vasoconstrictor angiotensin II, promoting fibrosis and increased portal pressure. Strong positive correlations were observed between ACE and virulence factors associated to the species of the Streptococcaceae family, suggesting a link between virulence factors and increased ACE levels. CXCL10 is a pro-inflammatory chemokine which has been shown to correlate with acute decompensation, ACLF severity and complications in subjects with severe portal hypertension. C-reactive protein has been identified as independent predictor of mortality and therefore represent significant targets for intervention. Immune cell activation is driven by bacterial translocation in cirrhosis which is a potential mechanism for this observation. These data confirm observations in previous studies in animal models.

[0274] Endothelial dysfunction is a feature of cirrhosis, which is associated with systemic inflammation (44, 45). It was therefore not surprising to note a reduction in ADMA in the YaqOOl treated patients, which is commensurate with the reduction in the severity of portal hypertension and improvement of blood pressure and renal dysfunction observed in animal studies. No such correlate was observed in the present study as the patients had relatively compensated cirrhosis.

[0275] Gut dysbiosis and inflammation perpetuate loss of gut barrier integrity and pathological bacterial translocation in cirrhosis (3, 46). Existing data reveal that acute decompensation is associated with a highly inflamed and permeable gut barrier.

[0276] Decrease in the Lactulose / L-Rhamnose ratio after YaqOOl treatment suggest a stronger gut barrier. Although the exact mechanism has not been elucidated, there were trends towards a positive modulation of fecal cytokines, which are likely contributors.

[0277] Previous studies in animal models demonstrated favorable effects on organ injury, immune activation status and hemodynamic profile. The results of this first-in-man randomized; placebo-controlled trial suggest that oral YaqOOl at a dose of 4g nocte is well tolerated with a favorable safety profile. Despite the rapid adsorption kinetics for bacterial toxins and metabolites, YaqOOl had no significant effect on micronutrient levels or impact on nutritional profile as assessed by the gold standard Royal Free Global Assessment tool.

[0278] The changes in the metagenomic composition due to YaqOOl treatment lead to speculation some of the differentially abundant extracellular bacterial components, which under ordinary conditions facilitate the binding and invasion, might beinteracting with the surface of the non-absorbable carbon beads (see Figure 14), leading to a selective decrease of the strains enriched in such elements, along with other genomic elements commonly observed in those strains, such as AMR genes. In turn, this would ameliorate the gut damage inflicted by such bacterial species, and in consequence leading to an improvement in gut health.

[0279] In conclusion, these findings support the potential of YaqOOl to address key pathophysiological mechanisms underlying complications of cirrhosis, particularly its effect on the microbiome composition (e.g. its virulence and AMR) which were associated with significant impact on markers of inflammation, endothelial function and gut permeability. Further, this trial provides the unexpected result that YaqOOl reduces the presence of microbial genes associated with biofilm formation and antibiotic resistance. This new, and surprising finding, has not previously been documented, and supports to the provision of YaqOOl as a new therapeutic route for addressing these particularly challenging aspects of medicine.

[0280] References

[0281] 1. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59-64.

[0282] 2. Smith ML, Wade JB, Wolstenholme J, Bajaj JS. Gut microbiome-brain-cirrhosis axis. Hepatology. 2024;80(2):465-85.

[0283] 3. Sole C, Guilly S, Da Silva K, Llopis M, Le-Chatelier E, Huelin P, et al. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology. 2021;160(l):206-18.el3.

[0284] 4. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology. 2009;50(2):638-44.

[0285] 5. Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Alvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022; 19(2): 112-34.

[0286] 6. Caraceni P, Vargas V, Sola E, Alessandria C, de Wit K, Trebicka J, et al. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021;74(3): 1660-73.

[0287] 7. Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, et al. Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022;76(2):332-42.8. Engelmann C. Rifaximin in cirrhosis: Is its microbiological spotless record under threat? J Hepatol. 2025;82(2):392-4.

[0288] 9. Fernandez J, Prado V, Trebicka J, Amoros A, Gustot T, Wiest R, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol. 2019;70(3):398-411.

[0289] 10. Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2019;156(5):1368-80.el0.

[0290] 11. Huemer M, Mairpady Shambat S, Brugger SD, Zinkemagel AS.

[0291] Antibiotic resistance and persistence-implications for human health and treatment perspectives. EMBO Rep. 2020;21(12):e51034.

[0292] 12. Macnaughtan J RI, Soeda J, Sawhney R, Oben J, Davies N et al. 0091 : Oral therapy with non-ab sorbable carbons of controlled porosity (YAQ001) selectively modulates stool microbiome and its function and this is associated with restoration of immune function and infammasome activation. J Hepatol. 2015;62:S240.

[0293] 13. Macnaughtan J RI, Soeda J, Sawhney R, Oben J, Davies N et al. PTH-095 Oral carbon therapy is associated with a selective modulation of the microbiome in cirrhotic rats which is associated with a significant reduction in inflammatory activation. Gut. 2015;64:A449-A50.

[0294] 14. Liu J, MacNaughtan J, Kerbert AJC, Portlock T, Martinez Gonzalez J, Jin Y, et al. Clinical, experimental and pathophysiological effects of YaqOOl: a nonabsorbable, gut-restricted adsorbent in models and patients with cirrhosis. Gut.

[0295] 2024;73(7): 1183-98.

[0296] 15. Van der Merwe SW, M GF-B. Safe and successful gut-restricted adsorbent strategy against cirrhosis and acute-on-chronic liver failure. Gut. 2024.

[0297] 16. Macnaughtan J AA, Kerbert A, Vargas V, Durand F, Gine P et al. 009 A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (YaqOOl) in cirrhotic patients. Gut. 2021;70:A5-A6.

[0298] 17. Riva A, Gray EH, Azarian S, Zamalloa A, McPhail MJW, Vincent RP, et al. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Rep. 2020;2(6):100151.

[0299] 18. Criscuolo A, Brisse S. AlienTrimmer: a tool to quickly and accurately trim off multiple short contaminant sequences from high-throughput sequencing reads. Genomics. 2013;102(5-6):500-6.19. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol.

[0300] 2014;32(8):834-41.

[0301] 20. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature.

[0302] 2013;500(7464):541-6.

[0303] 21. Plaza Onate F, Le Chatelier E, Almeida M, Cervino ACL, Gauthier F, Magoules F, et al. MSPminer: abundance-based reconstitution of microbial pangenomes from shotgun metagenomic data. Bioinformatics. 2019;35(9): 1544-52.

[0304] 22. Fan Y, Stoving RK, Berreira Ibraim S, Hybtylainen T, Thirion F, Arora T, et al. The gut microbiota contributes to the pathogenesis of anorexia nervosa in humans and mice. Nat Microbiol. 2023;8(5):787-802.

[0305] 23. Ruppe E, Ghozlane A, Tap J, Pons N, Alvarez AS, Maziers N, et al. Prediction of the intestinal resistome by a three-dimensional structure-based method. Nat Microbiol. 2019;4(l): 112-23.

[0306] 24. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res. 2005;33(Database issue):D325-8.

[0307] 25. Das P, Marcisauskas S, Ji B, Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics. 2019;20(l):517.

[0308] 26. Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol.

[0309] 2009;297(l):G98-gl06.

[0310] 27. Ferrigno A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World J Gastroenterol. 2015;21 (17): 5131 -7.

[0311] 28. Lembas A, Mikula T, Sapula M, Barczak S, Badura B, Wiercinska Drapalo A. The correlation of ADMA with proinflammatory, liver injury and cancer biomarkers in patients with liver dysfunction. Hepatol Forum. 2024;5(4): 171-7.

[0312] 29. Onate FP, Chamignon C, Burz SD, Lapaque N, Monnoye M, Philippe C, et al. Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. Int J Mol Sci. 2023;24(15).30. Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab.

[0313] 2019;30(4):675-88.e7.

[0314] 31. Zou Q, Li Y. Hypervirulent Klebsiella pneumoniae. N Engl J Med.

[0315] 2021;385(9):833.

[0316] 32. Mbaye B, Magdy Wasfy R, Borentain P, Tidjani Alou M, Mottola G, Bossi V, et al. Increased fecal ethanol and enriched ethanol -producing gut bacteria Limosilactobacillus fermentum, Enterocloster bolteae, Mediterraneibacter gnavus and Streptococcus mutans in nonalcoholic steatohepatitis. Front Cell Infect Microbiol.

[0317] 2023;13:1279354.

[0318] 33. Sharma AK, Dhasmana N, Dubey N, Kumar N, Gangwal A, Gupta M, et al. Bacterial Virulence Factors: Secreted for Survival. Indian J Microbiol. 20I7;57(I): 1-10.

[0319] 34. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023; 11(13).

[0320] 35. Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. Gut Microbes. 2013;4(5):382-7.

[0321] 36. Bajaj JS, Sikaroodi M, Shamsaddini A, HenselerZ, Santiago-Rodriguez T, Acharya C, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. Gut. 2021;70(6): 1162-73.

[0322] 37. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60(5):940-7.

[0323] 38. Bajaj JS, Shamsaddini A, Acharya C, Fagan A, Sikaroodi M, Gavis E, et al. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes. 2021; 13(1): 1993584.

[0324] 39. Crofts TS, Gasparrini AJ, Dantas G. Next-generation approaches to understand and combat the antibiotic resistome. Nat Rev Microbiol. 2017;15(7):422-34.

[0325] 40. Pena RT, Blasco L, Ambroa A, Gonzal ez -Pedraj o B, Fernandez-Garcia L, Lopez M, et al. Relationship Between Quorum Sensing and Secretion Systems. Front Microbiol. 2019; 10: 1100.

[0326] 41. Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol. 2009; 11(12):2970-88.42. Anthony WE, Bumham CD, Dantas G, Kwon JH. The Gut Microbiome as a Reservoir for Antimicrobial Resistance. J Infect Dis. 2021;223(12 Suppl 2):S209-sl3.

[0327] 43. Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF. The human microbiome as a reservoir of antimicrobial resistance. Front Microbiol. 2013;4:87.

[0328] 44. Efremova I, Maslennikov R, Poluektova E, Medvedev O, Kudryavtseva A, Krasnov G, et al. Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis. Int J Mol Sci. 2024;25(4).

[0329] 45. Nesci A, Ruggieri V, Manilla V, Spinelli I, Santoro L, Di Giorgio A, et al. Endothelial Dysfunction and Liver Cirrhosis: Unraveling of a Complex Relationship. Int J Mol Sci. 2024;25(23).

[0330] 46. Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol. 2021;18(3): 167-80.

Claims

CLAIMS1. Porous carbon particles for use in a method of preventing or treating a biofilm-mediated disease, wherein:said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm; andsaid method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said biofilm-mediated disease.

2. Porous carbon particles for use in a method of preventing or treating antibiotic resistance, wherein:said porous carbon particles comprise micropores of diameter 2 nm or less and mesopores / small macropores of diameter 30 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 30nm, and substantially no large macropores of diameter greater than 500 nm; andsaid method comprises administering the porous carbon particles to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

3. Porous carbon particles for use according to claim 1 or claim 2, wherein mesopores of diameter greater than 2 nm and less than 30nm and large macropores of diameter greater than 500 nm together make up 10% or less of the total pore volume of the porous carbon particles.

4. Porous carbon particles for use according to any one of claims 1 to 3, wherein 5 to 30% of the total pore volume of the porous carbon particles is made up of pores having a mean diameter of from 0.6 to 2 nm.

5. Porous carbon particles for use according to any one of claims 1 to 4, wherein 85% or more of the pore volume of the porous carbon particles which is made up of pores having a mean diameter greater than 2nm is made up of pores having a mean diameter of from 30 nm to 500 nm, preferably wherein 90% or more of the pore volume of the porous carbon particles which is made up of pores having a meandiameter greater than 2nm is made up of pores having a mean diameter of from 30 nm to 500 nm, preferably from 50 nm to 300 nm, preferably from 50 nm to 200 nm.

6. Porous carbon particles for use according to any one of claims 1 to 5, wherein the total pore volume is from 0.5 to 2.5 cm3g-l.

7. Porous carbon particles for use according to any one of claims 1 to 6, wherein the total pore volume is from 1.0 to 2.0 cm3g-l.

8. Porous carbon particles for use according to any one of claims 1 to 7, wherein the bulk density of the porous carbon particles is 0.10 gcm-3 to 0.30 gcm-3.

9. Porous carbon particles for use according to any one of claims 1 to 8, wherein the bulk density of the porous carbon particles is 0.15 gcm-3 to 0.25 gcm-3.

10. Porous carbon particles for use according to any one of claims 1 to 9, wherein the specific surface area is from 700 m2 / g to 2000 m2 / g.

11. Porous carbon particles for use according to any one of claims 1 to 10, wherein the specific surface area is from 900 m2 / g to 1400 m2 / g.

12. Porous carbon particles for use according to any one of claims 1 to 11, wherein the volume of pores having a mean diameter of from 0.5 to 2 nm in the porous carbon particles is 0.1 to 1.1 cm3g-l and the volume of pores having a mean diameter of from 30 to 500 nm is 0.8 to 2.5 cm3g-l.

13. Porous carbon particles for use according to any one of claims 1 to 12, wherein the particles are administered orally or rectally, preferably wherein the particles are administered orally in free-flowing form or in tablet form.

14. Porous carbon particles for use according to any one of claims 1 to 13, wherein the porous carbon particles are coated in order to control their release and adsorption properties, preferably wherein the porous carbon particles are coated with a film that will allow predominant release into the large bowel.

15. Porous carbon particles for use according to any one of claims 1, or 3 to 14, wherein the biofilm-mediated disease is an infection, a chronic infection, periodontitis, cystic fibrosis, urinary tract infection, infective endocarditis, a chronic wound or a disease resulting from ingestion of a substance or particle comprising a biofilm.

16. Porous carbon particles for use according to any one of claims 2 to 14, wherein the antibiotic resistance is associated with an infection or disease to be prevented or treated.

17. Porous carbon particles for use according to any one of claims 1 to 16, wherein the biofilm-mediated disease or antibiotic resistance is associated with the presence of Escherichia coli, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa, Enterob acteriaceae, coagulase-negative staphylococci, Streptococcus spp., Acinetobacter spp., Enterococcus spp pathogens, or a multidrugresistant (MDR) pathogen.

18. Porous carbon particles for use according to any preceding claim, wherein the porous carbon particles reduce the presence of virulence factors.

19. A method of treating or preventing a biofilm-mediated disease, the method comprising administering porous carbon particles as defined in any one of claims 1 to 14 to a subject in need thereof, thereby preventing or treating said biofilm-mediated disease.

20. Use of porous carbon particles as defined in any one of claims 1 to 14 in the manufacture of a medicament for treating or preventing a biofilm-mediated disease.

21. A method of treating or preventing antibiotic resistance, the method comprising administering porous carbon particles as defined in any one of claims 1 to 14 to a subject in need thereof, thereby preventing or treating said antibiotic resistance.

22. Use of porous carbon particles as defined in any one of claims 1 to 14 in the manufacture of a medicament for treating or preventing antibiotic resistance.